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CHAPTER I 
INTRODUCTION 
The primary goal of this dissertation research has been to in-
vestigate the effects of systemic interleukin-1 (IL-1) therapy on 
local immune function in an experimental murine tumor model. In this 
model, the administration of systemic IL-1 in conjunction with ad-
juvant therapy allows for enhanced development of tumor immunity (Hor-
nung and Mathews, 1985; Hornung, dissertation, 1987). Little is known 
about the ability of IL-1 to augment immune responsiveness in weakly 
immunogenic tumor systems. Because weakly immunogenic tumors respond 
less readily to some forms of therapy, the use of cytokines to enhance 
immune responsiveness may be a valuable addition to current thera-
peutic protocols. While the ability of IL-1 to affect various im-
munocompetent cells is well established in vitro, information involv-
ing its in vivo activities in tumor systems is more limited. Although 
other investigators have demonstrated the efficacy of IL-1 in promot-
ing host survival of tumor inoculation (Nakamura et al., 1986; North 
et al., 1988; McCune and Marquis, 1990), little is known about the IL-
1 effects which may lead to host protection. 
The current study examined the effects of systemic IL-1 therapy 
on regional lymphoid tissue draining the site of tumor challenge. 
This was accomplished by; in vitro assessments of lymph node cell 
populations from IL-1 treated and non-IL-1 treated animals, cytotoxic 
cell frequency analysis of the lymph node cells, the assessment of 
1 
2 
tumor-specific proliferation, and the identification of tumor-protec-
tive cell populations by in vivo adoptive transfer experiments. The 
results from this study provide information about the effects of IL-1 
in an in vivo tumor model, and aid in the assessment of IL-1 as a 
potential therapeutic agent. 
CHAPTER II 
REVIEW OF THE RELATED LITERATURE 
A. Interleukin-1: An overview. 
Interleukin-1 (IL-1) has been described as a basic mediator of 
intercellular communication both within the immune system, and be-
tween the immune system and virtually all other organ systems 
(di Giovine and Duff, 1990). IL-1 is produced in vivo by a variety of 
cell types, including monocytes (Gery and Lepe-Zuniga, 1984), tissue 
macrophages (Simon and Willoughby, 1981; Murphy et al., 1985), and 
lymphocytes (Scala et al., 1984; Matsushima et al., 1985; Tartakovsky 
et al., 1986). IL-1 is also produced by cells in the vasculature 
(Libby et al., 1986), skin (Luger et al., 1982), and brain (Fontana et 
al., 1984). Two forms of the cytokine have been identified (IL-1 
alpha and IL-1 beta) which have 26% amino acid homology and bind to 
the same receptor (Mosley et al., 1987). 
IL-1 has been shown to have a number of effects upon physio-
logical functions when administered to animals. These activities are 
important factors to consider when evaluating IL-1 as a potential 
therapeutic agent. The administration of IL-1 to animals or humans 
may affect other functions than those which are therapeutic. The 
effects of IL-1 administration on neurological functions include the 
induction of fever (Dinarello et al., 1986), increased adrenocor-
ticotropic hormone (ACTH) (Besedovsky et al., 1986), and increased 
slow-wave sleep (Krueger et al., 1984; Tobler et al., 1984). Effects 
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on metabolic functions include hypozincemia, hypoferremia, and hyper-
cupraemia (Kampschmidt and Pulliam, 1978), increased acute phase 
protein synthesis (Sipe et al., 1979; Dinarello et al., 1984), and in-
creased insulin and corticosteroid production (Besedovsky and del Rey, 
1987). These effects on metabolic functions may be relevant to the 
host response to infectious agents. IL-1 effects on endothelial and 
vascular cells result in hypotension (Dinarello, 1987; Okusawa et al., 
1988), increased leukocyte adherence (Bevilacqua et al. 1985) and 
chemoattractant effects (Hunninghake et al., 1986). These effects are 
important in lymphocyte trafficking, and in the inflammatory response. 
B. Effects of interleukin-1 on immunocompetent cells. 
IL-1 is known to modulate a number of hematopoietic and immuno-
logical processes which may result in the modification of a tumor 
immune response. IL-1 induces the production of a variety of 
hemopoietic growth factors (Rennick, et al., 1987; Zucali, et al., 
1987) and acts synergistically with certain colony stimulating factors 
to stimulate murine macrophage progenitors and primitive stem cells 
(Moore and Warren, 1987; Mochizuki et al., 1987). IL-1 administered 
in vivo can promote the cycling of hemopoietic stem cells in normal 
(Neta et al., 1987) and 5-fluorouracil-treated mice (Moore and Warren, 
1987), perhaps by inducing the production and/or release of hemato-
poietic growth factors. IL-1 treatment resulted in bone marrow cell 
enlargement and increased cycling of the enlarged cells. Bone marrow 
cells from IL-1 treated animals were better able to proliferate in the 
presence of granulocyte-monocyte colony stimulating factor (GM-CSF) in 
in vitro experiments. Other IL-1 effects upon hematologic cells in-
5 
elude radioprotection (Neta et al., 1986), and bone marrow stimula-
tion. 
IL-1 is known to affect a number of immunological cell 
populations. IL-1 has been shown to function as an immunological ad-
juvant in vivo (Staruch and Wood, 1983; Reed et al. 1989). In vitro, 
the cytokine can regulate a variety of cell surface receptors and 
determinants correlated with maturation and functional activation of 
not only T, but also B lymphocyte differentiation and proliferation 
(Lipsky et al., 1983; Pike and Nossal, 1985). IL-1 affects both rest-
ing and activated B cells, resulting in increased proliferation and 
plaque-forming activity (Chiplunkar et al., 1986). IL-1 also in-
creases antibody production in B cell lines (Giri et al., 1984). 
Therefore IL-1 may play a role in B lymphocyte growth and maturation. 
The role of IL-1 in T lymphocyte-mediated immune responses is 
well established. IL-1 functions as an activating signal for T cells 
(Larsson et al., 1980; Meuer and Meyer zum Buschenfelde, 1986), and 
can enhance T lymphocyte proliferation (Smith, 1980). IL-1 can aug-
ment the generation of helper and cytotoxic T lymphocytes by induction 
of interleukin-2 (IL-2) (Koopman et al., 1978; Farrar et al.,1980; 
McMannis and Plate, 1985). In addition, IL-1 has been reported to 
promote the generation of helper T lymphocytes and to diminish the 
generation of suppressor T cells (Durum et al., 1984; Durum et al., 
1985). IL-1 synergizes with interleukin-6 (IL-6) in the activation of 
CD4+ T cells (Houssiau et al., 1989; Holsti and Raulet, 1989), and 
modulates messenger RNA (mRNA) levels of activation-associated lym-
phokines in T lymphocytes (Hagiwara et al., 1987). IL-1 induces IL-2 
6 
production and increases T cell responsiveness to mitogens and anti-
gens in vitro. IL-1 also induces the production of interleukin-4 (IL-
4), as well as the increased expression of the IL-2 receptor (Lowen-
thal et al., 1986; Ho et al., 1987). 
IL-1 has been shown to contribute to the generation of cytotoxic 
T lymphocyte (CTL) and lymphokine activated killer (LAK) cell ac-
tivities, as well as the enhancement of natural killer (NK) cell ac-
tivities. IL-1 may act with IL-6 on cos+ cells to enhance CTL func-
tion (Renauld et al., 1989). In addition, the enhanced activity of 
cytotoxic cells may be generated indirectly due to the stimulatory 
effects of IL-1 on helper T cells and their subsequent production of 
IL-2 (Holsti and Raulet, 1989). In vitro experiments have suggested a 
role for IL-1 in the generation of LAK activity. IL-1 synergizes with 
IL-2 in the generation of LAK cells (Crump et al., 1989). The addi-
tion of IL-1 to LAK cell cultures resulted in enhanced proliferation 
(Aribia et al., 1987) and augmented lytic activity (Ochoa et al., 
1987). In addition, intratumoral injections of IL-1 in vivo resulted 
in the preferential homing of intravenously injected LAK cells to the 
tumor site (Migliori et al., 1987). 
IL-1 increases the binding of NK cells to tumor targets. Tumor 
cells can induce the synthesis of IL-1 by NK cells (Herman et al., 
1985). The same report has shown that patients with large tumor bur-
dens show significant reduction in IL-1 production with concomitant 
decreased killing activity of NK cells. The impaired NK function was 
reconstituted with exogenous IL-1. Davis et al. (1990) have shown an 
augmentation of in vivo NK activity with IL-1. IL-1 enhances NK func-
7 
tion synergistically with IL-2 and interferon gamma (Ostensen et al., 
1989). An NK-like cell line expressed increased binding of IL-2 and 
increased IL-2 receptor mRNA synthesis in response to IL-1 (Lubinski 
gt al., 1988). 
Based on its multiple effects on various cell populations, IL-1 
has a number of potential therapeutic uses. The in vivo administra-
tion of IL-1 can protect mammalian hosts against lethal challenges 
with microorganisms (Ozaki et al., 1987; Czuprynski and Brown, 1987; 
van't Wout, et al., 1988) and from lethal irradiation (Neta et al., 
1986). The radioprotective effects are due to IL-1 stimulation of 
bone marrow cells, and may be caused by the induction of large numbers 
of bone marrow cells into the radioresistant late S phase (Neta et 
al., 1987). The antimicrobial resistance caused by IL-1 treatment may 
be the result of an accumulation of neutrophils and mononuclear phago-
cytes. The antimicrobial and radioprotective effects of IL-1 may be 
useful in the prevention of infection in individuals undergoing vari-
ous cancer therapies. Morikage et al. (1990) evaluated the preventive 
capability of IL-1 alpha against bacterial infections in normal and 
anticancer drug-treated mice. Pretreatment with IL-1 resulted in 
enhanced survival of both the normal and drug-treated animals. 
The ability of IL-1 therapy to restore impaired T cell functions 
in vivo was demonstrated by Yamashita and Shirakawa (1987). They ex-
amined the effect of in vivo administration of recombinant human in-
terleukin 1 on T-cell functions in tumor-bearing mice using an in 
vitro assay system. In tumor-bearing animals, the in vitro induction 
of trinitrophenyl (TNP)-specific cytotoxic T cells and proliferative T 
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cell responses from spleen cells were impaired. The administration of 
IL-1 alpha or IL-1 beta resulted in a dose dependent restoration of 
impaired T and NK cell function and the activation of protective im-
munity against the tumor. 
c. Antitumor effects of interleukin-!. 
The potential use of IL-1 as an antitumor agent has been ex-
amined by several investigators. Nakamura et al. (1986) examined the 
antitumor effect of IL-1 alpha against various murine syngeneic 
tumors. By using large doses of IL-1 (l-30 ug per injection) they 
were able to demonstrate antitumor effects. These effects were gener-
ally dose and route dependent. Treatment with IL-1 in vivo inhibited 
the growth of a number of intradermally transplanted tumors, including 
the Meth A sarcoma in BALB/c mice, the 816 melanoma in C57Bl/6 mice, 
and the colon 26 adenocarcinoma in CDFl mice. Mice cured of the Meth 
A sarcoma were capable of rejecting the tumor upon rechallenge. In 
addition, IL-1 therapy was effective against the spontaneous pulmonary 
metastases of Lewis lung carcinoma in BDFl mice. The intradermal 
route was most effective, followed by intramuscular and intravenous 
injections. Intraperitoneal therapy was not assessed. Treatment 
regimes ranged from one dose of 10-30 ug to 7 daily doses of 1-10 ug. 
Several small-dose injections were as efficacious as one larger injec-
tion when administered intratumorally. IL-1 was most effective early 
after tumor inoculation (day 1 tumors responded better to treatment 
than did day 7 tumors). The authors suggest that the antitumoral 
activity of IL-1 may be due to direct cytotoxicity for the tumor 
cells, facilitated cytolysis of the tumor cells, or chemotactic ef-
9 
fects upon tumoricidal monocytes. In addition, the authors suggest 
that IL-1 may play a role in the establishment of immunity. In these 
same tumor systems, it was shown that concomitant therapy with in-
domethacin augmented the antitumor effect, in part by reducing the 
efficacious dose (Nakata et al., 1988). Prostaglandin E2 (PGE2) pro-
duced by the host cells in response to IL-1 and/or by the tumor mass 
may disrupt the antitumor activity of IL-1. PGE2 has known immunosup-
pressive properties for NK and macrophage-mediated cytotoxicity (Lala 
et al., 1986; Kunkel et al., 1986), T cell mitogenic responses (Barker 
et al., 1981) and cytokine production by lymphocytes (Walker et al., 
1983). The investigations by Nakamura et al. (1986) were among the 
first which indicated a possible role for IL-1 therapy in the treat-
ment of neoplasia. Disadvantages to the methods included the high 
doses of IL-1 required for tumor regression, and the appearance of 
tumor immunity in only one tumor model. In addition, the authors did 
not investigate possible mechanisms for the IL-1 effects. 
More recently, investigators have examined the effect of IL-1 
therapy on the generation of systemic immunity, in addition to re-
gression of primary tumors. Ebina and Ishikawa (1989) investigated 
the antimetastatic effects of recombinant human IL-1 beta. They found 
that intratumoral injections of IL-1 inhibited the growth of Meth A 
solid tumors. IL-1 treatment lead to the complete regression of es-
tablished tumors, and resistance to reinoculated tumors. In a double 
grafted tumor system, the authors found that intratumoral injections 
of IL-1 in one location had an effect on tumor growth in another re-
gion. This effect was dependent upon the presence of tumor cells in 
10 
the region of IL-1 injection. IL-1 therapy appeared to induce respon-
ses to the non-treated tumor of the double grafted tumor system, and 
therefore may bring about the regression of metastatic tumors. Spleen 
cells from immunized animals were capable of adoptively transferring 
tumor resistance. 
The ability of IL-1 to induce systemic immunity was also shown 
by its use as an adjuvant in specific immunotherapy (McCune and Mar-
quis, 1990). These authors administered IL-1 therapy in conjunction 
with a vaccine of irradiated line 1 alveolar cell lung carcinoma 
cells. Animals were rechallenged with viable tumor; those which had 
received 120-360 ng/dose of IL-1 therapy demonstrated an enhanced 
ability to survive tumor rechallenge. IL-1 therapy could be admini-
stered either locally (at the chest wall inoculation site) or distally 
(in the leg). Higher doses of IL-1 (720 ng/animal) proved to be less 
effective therapeutically, and produced signs of illness in the mice. 
Some suppression of weight gain was seen with 8 daily doses of 360 
ng/animal. IL-1 alpha, IL-1 beta, and an IL-1 peptide (163-171) all 
showed antitumor effects. These experiments suggest that IL-1 can act 
as a systemic adjuvant in this tumor system. Because IL-1 therapy was 
administered only at the time of tumor vaccination, the authors sug-
gest that IL-1 acts through its effects on cell populations, rather 
than directly against the tumor. 
Other investigators examined the effects of the IL-1 peptide 
(163-171) on the tumor immune response. This peptide is proposed to 
have the immunostimulatory effects of IL-1, without the potentially 
harmful inflammatory effects (Antoni et al., 1986). Forni et al. 
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(l989) examined the effects of both IL-1 beta and the IL-1 peptide on 
the poorly immunogenic CE-2 tumor in BALB/c mice. The peptide was 
administered at the tumor challenge site for 10 daily injections. 
While consistent inhibition of tumor growth was noted, it was less 
than that seen with intact IL-1 beta. The authors also investigated 
the effect of IL-1 therapy upon the efficacy of adoptive im-
munotherapy. Tumor cells were admixed in a 1 to 10 ratio with non-
reactive lymphocytes from tumor-bearing animals. Strong inhibition of 
tumor growth was demonstrated by animals which received local IL-1 
therapy along with the lymphocytes. This activity was abolished if 
the recipient animals were sublethally irradiated, treated with cyclo-
sporin A, or if L3T4+ or asialo GMl+ cells were removed. The authors 
suggest that L3T4+ cells may enhance host tumor reactivity by the 
release of cytokines. 
While investigators have reported direct IL-1 mediated cyto-
static and cytotoxic activities against some tumor cell lines (Onozaki 
et al., 1985b; Lachman et al., 1986), there is evidence to suggest 
that the antitumor effects of IL-1 are mediated in vivo by the action 
of various cell populations. As noted previously, IL-1 has multiple 
effects upon immunocompetent cells such as NK cells, T lymphocytes, 
and macrophages. A series of investigations utilizing antibody treat-
ment of cell populations, irradiated animals, and nude mice have im-
plicated T lymphocytes as potential mediators of the in vivo antitumor 
activities of IL-1 (Izumi et al., 1985; North et al., 1988; Belardelli 
et al., 1989). 
In mice transplanted with highly metastatic Friend leukemia 
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cells, subcutaneous injections of IL-1 beta resulted in a marked in-
crease in survival time, and inhibition of metastatic tumor growth in 
liver and spleen (Belardelli et al., 1989). Subcutaneous therapy with 
IL-2 resulted in inhibition of tumor growth, but not prevention of 
metastases. Combined treatment with IL-1 and IL-2 produced a syner-
gistic antitumor effect resulting in 60% survival. IL-1 and IL-2 
therapy had no antitumor effects in animals which had been treated 
with anti-Thy 1.2 antibody, or in nude mice. These experiments demon-
strate the ability of local IL-1 therapy to prevent the formation of 
metastases. The inclusion of IL-2 injections with the IL-1 therapy 
enhanced this effect. The antitumor activities of IL-1 and IL-2 ap-
peared to be dependent on host T lymphocytes. 
Izumi et al. (1985) evaluated the effect of in vivo administra-
tion of IL-1-containing culture fluid supernatants (CFS) on the induc-
tion of tumor-specific immunity. Animals were injected with viable 
syngeneic X5563 cells, followed by 5 consecutive subcutaneous or in-
traperitoneal injections of CFS. Lymph node cells or spleen cells 
from the CFS-treated animals exhibited enhanced CTL and delayed-type 
hypersensitivity (DTH) responses when compared with tumor-bearing 
animals which did not receive treatment. CTL responses were measured 
by in vitro sensitization with mitomycin c treated XSS63, followed by 
cytotoxicity assays. DTH responses were measured by adoptive transfer 
of immune cells and mitomycin c treated X5563 cells, followed by the 
measurement of footpad swelling 24 hours after transfer. Lymph node 
and spleen cells from treated animals also exhibited complete tumor-
neutralizing effects in Winn-type adoptive transfer assays. Antibody 
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depletion experiments demonstrated that Lyt 1+2- T cells were respon-
sible for both the DTH and tumor-neutralizing activities. Depletion 
of Thy 1.2+ or Lyt 1.1+ cells decreased these immune activities, while 
depletion of Lyt 2.1+ cells had no effect. The in vivo protective 
immunity was tumor-specific as demonstrated by the lack of activity 
against MH134 cells. These experiments demonstrated that IL-1 may 
increase CTL priming in lymph node and spleen, as well as increasing 
DTH and tumor-neutralizing activity. As suggested previously 
(Fujiwara et al., 1984), the adoptively transferred tumor-neutralizing 
activity appeared to be more closely associated with the DTH response, 
rather than with CTL generation. Because these authors used 
lipopolysaccharide (LPS)-stimulated culture supernatants instead of 
recombinant IL-1, it is unclear which effects are directly at-
tributable to IL-1 activity, and which may be the result of other 
factors. In addition, the actual doses of IL-1 administered are dif-
ficult to determine because the injection protocols list only the 
volume of supernatant injected. However, these experiments do suggest 
a possible role for IL-1 in the induction of tumor-specific immune ef-
fects, and imply that T lymphocytes may be mediators of these activi-
ties. 
In an immunogenic murine tumor model, North et al. (1988) found 
that systemic IL-1 therapy could induce T-cell-mediated tumor regres-
sion. Intraperitoneal injections of human recombinant IL-1 alpha were 
shown to cause complete regression of a relatively large, immunogenic 
murine sarcoma growing subcutaneously. The efficacy of IL-1 therapy 
was dependent on the number of IL-1 injections and the time at which 
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they were administered. Intraperitoneal IL-1 therapy was shown to be 
most effective against subcutaneous SAI sarcoma, and less effective 
against L51784 and P815. The authors suggest that this difference may 
be due to immunogenic differences between the tumors, and that less 
immunogenic tumors may be less responsive to IL-1 therapy. The tumor 
regression was dependent upon underlying concomitant T-cell mediated 
immunity, as determined by the timing of most effective therapy and 
experiments with various phenotypic cell populations. IL-1 therapy 
was most effective when administered after an immune response to the 
tumor was underway, and was not therapeutic if given too early during 
tumor growth. In addition, experiments in T cell deficient mice in-
fused with donor spleen cells showed that removal of either CD4+ or 
cos+ cell populations abrogated the antitumor effects. In this sys-
tem, IL-1 appeared to promote tumor regression by stimulating an in-
crease in SAI-sensitized T cells, thereby converting a subtherapeutic 
cell number to a therapeutic response. IL-1 augmented the response to 
tumors of sufficient immunogenicity by expanding host populations 
responsive to the tumor. These experiments showed that systemic IL-1 
therapy was capable of mediating effects against tumors, and that T 
lymphocytes were involved in this response. 
Taken together, the investigations performed thus far suggest 
that IL-1 may be useful in the treatment of immunogenic tumors. How-
ever, few of the groups have examined the immunological basis of the 
increased tumor protection induced by IL-1 treatment. Investigators 
have found that the augmenting effect of IL-1 may be mediated by T 
lymphocytes in immunogenic tumor systems (North et al., 1988; Belar-
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delli m;. al., 1989). These authors were able to demonstrate immunity 
only with immunogenic tumors, and suggest that weakly immunogenic 
tumors are less likely to respond to IL-1 therapy. In most of the 
tumor systems examined, relatively large doses of IL-1 are necessary 
to promote tumor survival (Nakamura et al., 1986, North et al., 1988). 
These high doses may cause the disruption of other physiological pro-
ceases affected by IL-1 administration. Few examinations have been 
made of low-dose IL-1 therapy in the treatment of weakly immunogenic 
tumors, or of its use in conjunction with other forms of anticancer 
treatment. 
In the current investigation, the tumor system to be examined is 
the EL-4 lymphoma of C57Bl/6 mice. EL-4 is an NK-resistant T-cell 
lymphoma of low immunogenicity, which rapidly progresses to produce a 
high degree of mortality in its syngeneic host (Cantrell et al., 1979; 
Gorer, 1950). Non-viable microorganisms have been shown to exert 
antitumor effects against the EL-4 lymphoma in vivo (Mathews, 1981; 
McDaniel and Cozad, 1982). Animals which received the EL-4 lymphoma 
' 
without local adjuvant therapy with Corynebacterium parvum succumbed 
to the tumor (Hornung and Mathews, 1985; Hornung, dissertation, 1987). 
In contrast, animals which received Q. parvum showed an increased sur-
vival rate with a high percentage of the animals remaining tumor-free. 
However, when these animals were rechallenged with EL-4 tumor cells, 
none of the animals survived. These results suggested that no sys-
temic immunity was generated as a consequence of Q. parvum treatment 
of the EL-4 lymphoma. These results are consistent with previous re-
ports which demonstrated that adjuvant therapy of less immunogenic 
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tumors resulted in survival of the animals, but no subsequent systemic 
immunity to the tumor (Dye et al., 1981; McDaniel and Cozad, 1982). 
An experimental protocol has been developed, whereby systemic 
IL-1 therapy is administered in conjunction with local adjuvant ther-
apy (Hornung and Mathews, 1985; Hornung, dissertation, 1987). Animals 
treated with both IL-1 and g. parvum at the time of primary tumor 
challenge demonstrate significantly enhanced survival upon rechal-
lenge. The survival rate was related in a dose dependent manner to 
the amount of IL-1 administered. Maximal survival was seen with the 
administration of 500 U (60 ng) of IL-1 per injection (2500 U total 
dose). The effective IL-1 doses were much lower than those used by 
other investigators. These results suggest that administration of IL-
1 during the primary tumor challenge modifies the host environment, 
resulting in an enhancement of tumor immunity. 
In summary, it is apparent that IL-1 can function to augment a 
variety of compartments of the immune system which may play a role in 
host immunity. As described earlier, other investigators have ex-
amined the use of IL-1 as a therapeutic agent in various tumor sys-
tems. However, the ability of IL-1 to augment other forms of im-
munotherapy has not been well characterized. In particular, little 
research has been conducted utilizing tumors of weak immunogenicity, 
which may require multiple modalities of treatment. In addition, most 
studies used relatively large doses of IL-1, which may have deleter-
ious effects in vivo. 
The objective of this study was to investigate the nature of the 
local lymphoid responsiveness generated by IL-1 treatment in an ex-
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perimental murine tumor model, and to evaluate low-dose IL-1 as an 
immune-augmenting agent in animals undergoing adjuvant therapy of a 
weakly immunogenic tumor. 
CHAPTER III 
MATERIALS AND METHODS 
A. Animals. 
Female C57Bl/6 mice, 7 to 8 weeks of age were obtained from 
Jackson Laboratories (Bar Harbor, ME) and acclimated for one to two 
weeks prior to use. Cell number, phenotypic, proliferative, and cyto-
toxic experiments were performed concurrently using three groups of 
five animals each, per treatment protocol, per day post tumor chal-
lenge (225 total). Adoptive transfer assays were performed using a 
total of 154 animals as cell donors, and 160 animals as cell recipi-
ents. Limiting dilution analysis experiments were performed using 
groups of 10 animals per treatment group, per day post tumor challenge 
(210 total). Antigenic responsiveness assays were performed on 5 
animals per group, per day (40 total). 
B. Cytokines. 
Recombinant human IL-1 alpha (specific activity 8.6 x 106 U/mg) 
was generously provided by Dr. Peter Lomedico (Hoffmann-LaRoche Inc., 
Nutley, N.J.). One unit of activity produced half maximal prolifera-
tion in the thymocyte co-stimulation assay. Prior to use in thera-
peutic injections, the IL-1 was diluted in Hank's balanced salt solu-
tion (HBSS, GIBCO Laboratories, Grand Island, NY) adjusted to pH 7.4 
with sodium bicarbonate and supplemented with 0.01% human serum al-
bumin. Human recombinant IL-2 (activity 2.5 x 106 U/ml) was provided 
by Cetus Corporation (Emeryville, CA). 
18 
19 
c. cell lines. 
The EL-4 lymphoma, a 7,12 dimethylbenz(a)-anthracene induced 
tumor syngeneic in the C57Bl/6 mouse, was obtained from Dr. R. Herber-
man. The YAC-1 lymphoma is a Moloney murine virus-induced lymphoma 
(Sjogren and Hellstrom, 1965) which was obtained from Dr. J. Clancy, 
Loyola University of Chicago, Maywood, IL. The P815 mastocytoma 
(ATCC-TIB-64)(Plaut et al., 1973) was obtained from the American Type 
culture Collection (Rockville, MD). The Lewis lung carcinoma (LLC) 
was obtained from Dr. M.R. Young, Hines Veterans Administration Hospi-
tal, Hines, IL. 
The cell lines were maintained in vitro in complete medium [RPMI 
1640 supplemented with 10% heat-inactivated fetal bovine serum (FBS, 
Hazleton Biologics Inc., Lenexa, KS), 2 mM L-glutamine, 0.1 mM non-
essential amino acids, 100 U/ml penicillin, 100 ug/ml streptomycin, 
0.25 ug/ml fungizone (GIBCO Laboratories, Grand Island, NY), and con-
taining 5 x 10-5 2-mercaptoethanol (Sigma Chemical Co., St. Louis, 
Mo. ) ] • 
D. In vivo tumor model. 
1. Tumor inoculation. 
Mice were inoculated intradermally in the right flank with 0.2 
ml of an admixture of 5 x 109 heat-inactivated Corynebacterium parvum 
and 5 x 103 EL-4 lymphoma cells in HBSS. Animals receiving IL-1 ther-
apy were treated with five equal dosages of 0.1 ml each, administered 
intraperitoneally on alternate days beginning on the day of tumor 
challenge. Except where noted, animals received 500 U of IL-1 per 
injection. The ~- parvum strain 4182 was obtained from the Pasteur 
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Institute (Paris, France) and cultured anaerobically. The organisms 
were heat-killed at ao0 c for 30 min prior to use. EL-4 cells for 
tumor injections were maintained in vivo by weekly passage, and were 
removed from the peritoneal cavity and washed once in HBSS immediately 
before use. 
2. Lymph node cell preparation. 
Axillary and brachial lymph nodes draining the tumor site were 
excised. Single cell suspensions were prepared in HBSS by passage 
through 60-gauge wire mesh and the cells were washed and counted by 
hemocytometer. Cell viability was determined by trypan blue ex-
clusion. 
E. Phenotypic analysis of lymph node cell populations. 
Antibodies used to analyze the phenotype of various lymph node 
cell populations included; monoclonal anti-mouse CDS (anti-Lyt 2.2, 
clone 53-6.7, biotin-conjugated), monoclonal anti-mouse Thy 1.2 (clone 
30H12, biotin-conjugated), and monoclonal anti-mouse CD4 (anti-L3T4, 
clone GK 1.5, phycoerythrin-conjugated), all from Becton-Dickinson 
(Mountain View, CA). Streptavidin-phycoerythrin was obtained from 
Vector Laboratories (Burlingame, CA). 
Lymph node cells (1 x 106 per marker assessed) were prepared for 
phenotyping by washing once with cold phosphate buffered saline (PBS, 
0.145 M sodium chloride, 0.02 M sodium phosphate, pH 7.4). The cells 
were incubated with the primary antibody for one half h in an ice 
bath. Following washes in cold PBS, cells were incubated with the 
secondary antibody for an additional half h on ice, protected from 
light. The cells were washed in cold PBS, and then fixed with 0.1 ml 
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of 1% paraformaldehyde in 0.15 M NaCl solution and stored at 4°c. The 
samples were washed and resuspended in 0.1 PBS prior to flow cyto-
metric analysis (FACS Analyzer IFA, Becton-Dickinson, Mountain View, 
CA). The number of cells expressing each surface marker was deter-
mined by multiplying the lymph node cell number by the percent posi-
tive cells. 
F. Adoptive transfer assay. 
Lymph node cells, prepared as in D.2., were admixed with 5 x 103 
EL-4 and injected intradermally into naive animals. Lymph node cell 
to EL-4 ratios of 500:1 in a total volume of 0.5 ml were used. Other 
animals were injected with the EL-4 tumor alone. In some experiments 
certain cell populations were removed by complement-mediated depletion 
prior to use in the adoptive transfer assay. The rate and size of 
tumor formation were assessed by measurement of perpendicular dia-
meters on various days following tumor inoculation. 
G. Complement-mediated cell depletion. 
Antibodies used to deplete certain lymph node cell populations 
included monoclonal anti-CD4 (anti-Lyt 1.2, clone CG16, 1:10 dilution) 
and monoclonal anti-CDS [anti-Lyt 2.2, clone AD4(15), 1:20 dilution] 
both from Accurate Chemical and Scientific Corp. (Westbury, NY). 
Rabbit anti-asialo GMl was obtained from Wako Chemicals USA, Inc. 
(Dallas, TX), and used at a 1:33 dilution. Antibodies were diluted in 
HBSS with 1% FBS immediately prior to use. 
Lymph node cell preparations were depleted of cells bearing spe-
cific cell markers by incubating 1 x 107 lymph node cells with 0.5 ml 
of diluted antibody for 1 h in an ice bath. The cells were washed 3 
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times with HBSS with 1% FBS to remove excess antibody and then 100 ul 
of Low Tex M rabbit complement (Accurate Chemical and Scientific 
corp., Westbury, NY) was added to the cell pellet. After 1 h of in-
cubation in a 37°c water bath, the cells were washed and resuspended 
and cell viability determined by trypan blue exclusion. These cells 
were then used in adoptive transfer assays as described in section F. 
H. IL-2 responsiveness. 
1. In vitro proliferation in response to IL-2. 
Lymph node cells prepared as in D.2. were cultured in 96-well 
flat-bottomed plates (Corning Glass Works, Corning, NY) at 5 x 105 
cells/ml in complete medium containing 1500 U/ml of IL-2 (total well 
volume equaled 0.2 ml). The lymph node cells were incubated at 37°c 
and 5% C02 for 5, 6 or 7 days, after which 1.0 uCi of [ 3H]thymidine 
(ICN Radiochemicals, Irvine, CA) was added to each well. After 6 h of 
incubation, the cells were harvested with a Cambridge PHO automated 
cell harvester (Cambridge Technology, Cambridge, MA) and the amount of 
radiolabel incorporation for each sample determined using a Beckman LS 
) 
5801 liquid scintillation counter (Beckman Instruments, Irvine, CA). 
Data are expressed as stimulation indices (SI): 
dpm experimental 
SI ----------------
dpm control 
2. In vitro stimulation with IL-2. 
Lymph node cells, prepared as in D.2., were cultured in 24-well 
plates (Becton-Dickinson & Co., Lincoln Park, NJ) at 2.5 x 106/ml in 
complete medium containing 1500 U/ml of IL-2 (total well volume 
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equaled 1 ml). After 7 days of culture at 37°c and 5% C02, the cells 
were removed from the plates and collected by centrifugation. The 
cell pellet was resuspended in 5 ml of HBSS and layered onto 5 ml of 
lymphocyte separation medium (Organon Teknika Corp., West Chester, 
PA). After centrifugation for 20 m, the viable cells were collected 
from the interface, washed once in HBSS, resuspended in complete medi-
um, and quantified as in section D.2. Some of these cells were used 
in chromium release assays as described in section I. below. 
r. Chromium release assay. 
Tumor cells were radiolabeled by incubation of 2 x 106 cells 
with 100 uCi sodium c51cr]chromate (DuPont NEN, Wilmington, DE) for 1 
h at 37°c with frequent agitation. After three washes in HBSS, the 
cells were resuspended in complete medium at 5 x 104 /ml and 0.1 ml 
volumes placed in 96-well round-bottomed plates (Corning Glass Works, 
Corning, NY) with varying effector cell numbers. Effector to target 
ratios of 50:1, 25:1, 12:1 and 6:1 were utilized. All assessments 
were performed in triplicate. Following 4 h of incubation the super-
natants were removed using a Skatron harvesting press (Skatron Inc., 
Sterling, VA) and associated radioactivity determined with a 4/600 ME 
PLUS automatic gamma counter (ICN Micromedic systems, Horsham, PA). 
Percent specific release was calculated by the following formula: 
(cpm experimental) - (cpm spontaneous) 
% specific release = -------------------------------------- X 100. 
(cpm maximum) - (cpm spontaneous) 
Spontaneous release was determined by incubation of labeled target 
cells with medium alone. Maximum release was determined by 0.5% Non-
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idet p-40 (Sigma Chemical Co., St. Louis, MO) lysis of labeled cells. 
Linear regression analysis was used to determine the number of lytic 
units/107 cells. One lytic unit was defined as the number of cells 
required to specifically lyse 30% of the target cells. 
J. Limiting dilution assay. 
Lymph node cells were harvested from animals injected with g. 
parvum and EL-4, or g. parvum and EL-4 with IL-1 therapy. Axillary 
and brachial lymph nodes were removed on various days post-tumor chal-
lenge, and single cell suspensions prepared. The cells were cultured 
in 96-well plates at concentrations of 1 x 104 , 5 x 104 and 1 x 
105 /well with 12 replicates of each dilution. Following a 7 day in-
cubation with 120 U/well (800 U/ml) of IL-2, 5 x 103 chromium-labeled 
target cells were added to each well. On a per cell basis, the con-
centration of IL-2 used in the limiting dilution assay corresponds to 
at least twice that used in the IL-2 stimulation protocol above. EL-
4, YAC-1 and P815 were used as tumor targets. After 4 h of incubation 
at 37°C, the amount of chromium released in each well was quantified 
as in Section I. above. The wells were scored as positive for cyto-
toxic activity when the chromium release exceeded 3 SD over the mini-
mum release of chromium. Estimates of precursor frequencies were made 
by the minimal chi-square method (Taswell, 1981). 
Preliminary experiments with lower IL-2 doses in culture 
resulted in a non-linear relationship between the fraction of non-
responding wells and the input cell number, when plotted semi-
logrithmically. This phenomenon was particularly apparent at low 
lymph node cell numbers and may indicate the loss of a cell necessary 
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for cytotoxic development. In order for accurate assessments of pre-
cursor frequency to be made, the precursor must be the only limiting 
factor (Miller, 1982). The use of supraoptimal IL-2 concentrations 
overcame this deficiency and permitted assessment of precursor fre-
quency. 
K. Antigenic responsiveness assay. 
1. Secondary tumor challenge. 
IL-1 treated and untreated animals which survived the primary 
tumor challenge were rechallenged on the opposite (left) flank with 
either 5 x 104 EL-4 or LLC in 0.1 ml of HBSS. Axillary and brachial 
lymph nodes draining the site of rechallenge were removed on various 
days post secondary challenge and were assessed for antigenic respon-
siveness to EL-4 or LLC in vitro as described below. 
2. Stimulation in vitro. 
EL-4 or LLC cells (4.5 x 107 ) were incubated with 100 ug of 
sterile-filtered mitomycin c (Sigma Chemical Co., St. Louis, MO) in a 
1 ml volume of complete medium with 1% FBS in a 37°c water bath with 
agitation at frequent intervals. After 1 h of incubation the cells 
were washed 3 times with HBSS and resuspended in complete medium with 
1% FBS. 
Lymph node cells from animals undergoing secondary tumor chal-
lenge (see above) were used as responder cell populations. The re-
sponders were plated at 5 x 105 cells/well with either 2 x 105 or 4 x 
105 of EL-4 or LLC. Control wells consisted of responders alone or 
stimulators alone. All assessments were performed in replicates of 
three or five. The cells were incubated for 7 days, after which 1 uCi 
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of [3H]thymidine (ICN Radiochemicals, Irvine, CA) was added to each 
well. After 6 h of incubation the cells were harvested and analyzed 
as described above. 
L. Statistical analysis. 
statistical analyses of differences in cell number, prolifera-
tion, and cytotoxicity between IL-1 treated and untreated mice were 
performed by the two-tailed Students t-test. The 95% confidence lev-
els obtained from the minimal chi-square analysis (Taswell, 1981) were 
used to analyze the limiting dilution data. The two-tailed Students 
t-test was used to assess differences in day of tumor appearance and 
animal survival in the adoptive transfer assays, while chi-square 
analysis was used to assess total survival data. 
CHAPTER IV 
RESULTS 
Systemic administration of interleukin-!, in conjunction with 
adjuvant therapy, provides for animal survival and the generation of 
tumor immunity in the tumor model utilized (Hornung and Mathews, 
1985). IL-1 may augment local lymphoid responsiveness to the tumor, 
and therefore allow for enhanced host survival. An examination was 
made of the lymph nodes draining the site of tumor challenge in order 
to assess the ability of IL-1 to modulate local immune responsiveness. 
A. Effect of IL-1 treatment on lymph node cell number. 
The ability of IL-1 to increase the number of lymph node cells 
draining the site of antigenic challenge was evaluated. Lymph node 
cells were derived sequentially from animals that had been challenged 
with adjuvant and tumor and either administered IL-1 (500 U/injection) 
or no further treatment (225 total animals; 3 groups of 5 each, per 
treatment group, per day post tumor challenge). An earlier increase 
' in lymph node cell number was observed in animals which received IL-1, 
when compared to those animals which did not (Fig. 1.). No difference 
in lymph node cell number was observed between the two groups of ani-
mals on days 0 through 2 post tumor and adjuvant administration. When 
compared to the day 1 values, both groups showed a cell number in-
crease beginning on day 3 for the IL-1 treated (p<0.01) and on day 5 
for the non-IL-1 treated animals (p<0.05). This cell number increase 
continued until day 6. The cell numbers for the IL-1 treated animals 
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Fig. 1. 
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Effect of IL-1 treatment on lymph node cell number. 
Brachial and axillary lymph nodes draining the site of 
tumor challenge were sequentially derived from IL-1 treated 
( e) and non-IL-1 treated (0) animals. Single cell 
suspensions were prepared and the total number of lymph 
node cells/animal determined by trypan blue exclusion. 
Cell number values represent the mean of 3 groups of 5 
animals each ± SE. Average lymEh node cell numbers for 
naive animals (4.8 ± 0.091 x 10 ) are represented by the 
filled square ( •). In this experimental model, tumor 
cells do not appear in the regional lymph nodes prior to 17 
days after intradermal injection. 
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were significantly higher when compared to the non-IL-1 treated group 
on days 3 (p<0.02), 4 (p<0.02), and 5 (p<0.05) post tumor challenge. 
Maximal cell numbers were recovered on day 4 for the IL-1 treated 
group and day 6 for the non-IL-1 treated animals. Lymph node cell 
numbers for both of the treatment groups declined by day 7. These 
data indicate that systemic IL-1 therapy significantly increased the 
number of lymph node cells draining the site of antigenic challenge in 
animals bearing tumors. The increase in lymph node cell number was 
both earlier and greater than that seen in non-IL-1 treated animals. 
B. Phenotypic analysis of draining lymph node cells. 
The observed increase in lymph node cell number may represent an 
overall expansion of cells in the lymph nodes, or alternatively may 
represent an increase in only a single cell population. Using the 
same animals as above, phenotypic analysis of draining lymph node 
cells was performed in order to determine the cell types responsible 
for the cell number increase. Lymph node cells from IL-1 treated and 
non-IL-1 treated animals were assessed for their expression of Thy 
1.2, CDS, and CD4 cell surface markers. The actual number of cells 
bearing these surface markers increased in the IL-1 treated animals, 
when compared to the non-IL-1 treated group (Fig. 2). The cell number 
increase was due predominately to an increase in Thy 1.2+ cells. 
Enhanced numbers of Thy 1.2+ cells were present in the IL-1 treated 
animals on days 3 (p<0.02) and 4 (p<0.01) post tumor challenge, with 
maximal numbers on day 6. The cell number increase was further 
characterized by assessing the expression of CD4 and CDS cell surface 
markers. Phenotypic analysis determined that the cell number increase 
Fig. 2. 
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Phenotypic analysis of lymph node cells. Lymph node cells 
from IL-1 treated ( •) and non-IL-1 treated ( o) animals 
were assessed for their expression of T cell markers. The 
positive cell number/animal was determined by multiplying 
the percent positive cells by the lymph node cell number-
/animal and is expressed as the mean value ± SE. The 
filled squares ( •> represent the number of cells express-
ini these surface markers in naive animals: 4.2 + 0.079 x 
10 for Th~ 1+, 1.42 ± 0.027 x 106 for CDS+, and 1.96 + 
0.037 x 10 for CD4+. Data points represent the mean of 
three groups of 5 animals each. 
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in IL-1 treated animals was due to an increase in both C04 and COB 
cells. The cos+ cell numbers were higher in the IL-1 treated animals 
on days 2 (p<0.05), 3 (p<0.02) and 4 (p<0.02) post tumor challenge, 
while an increased number of CD4+ cells were present on days 3, 4, and 
s (p<0.02, p<0.02, and p<0.01, respectively). The coa+/co4+ ratio 
remained constant (-1.0) regardless of the treatment group. These 
data indicate that IL-1 treatment increased numbers of T lymphocytes 
in the lymph nodes draining the site of tumor challenge. The increase 
in T lymphocytes was a consequence of increases in either co4+ or cos+ 
lymphocytes. 
c. Adoptive transfer assays. 
1. Effect of lymph node cells on tumor development and animal sur-
vival. 
Increased numbers of T lymphocytes in the draining lymph nodes 
of IL-1 treated animals may enhance the ability of these animals to 
respond to the tumor. Adoptive transfer assays were utilized to as-
sess the ability of lymph node cells from IL-1 treated and non-IL-1 
treated animals to mediate tumor protective effects against EL-4 in 
vivo. Lymph node cells were derived from IL-1 treated and non-IL-1 
treated animals, admixed with EL-4, and adoptively transferred into 
naive mice (day 3, n = 8 per group; day S, n = 8 per group; day 7, n 
20 for IL-1 treated group, n = 12 for non-IL-1 treated group, and n = 
20 for EL-4 alone group). Lymph node cells which were derived 7 days 
post tumor challenge from animals which received systemic IL-1 therapy 
demonstrated an ability to delay tumor development, while lymph node 
cells derived 3 or 5 days after tumor challenge did not (Fig. 3). An 
Fig. 3. 
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Effect of day 3, 5 and 7 lymph node cells from IL-1 treated 
and non-IL-1 treated animals on tumor development. Lymph 
node cells from IL-1 treated ( • ) and non-IL-1 treated (fl ) 
animals were removed on days 3, S, and 7 post primary tumor 
challenge. The cells were admixed with a 5 x 103 EL-4 in a 
500:1 lymph node cell to EL-4 ratio and injected intrader-
mally into naive animals (day 3, n = 8 per group; day S, n 
= 8 per group; day 7, n = 20 for EL-4 alone group, n = 20 
for IL-1 group, n = 12 for non-IL-1 group). The animals 
were examined periodically for the appearance of tumors. 
Animals injected with EL-4 alone (O) were assessed also. 
These data are the summary of 3 experiments. 
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equal number of day 7 lymph node cells from non-IL-1 treated donors 
also had no effect. Twenty-five percent (4/16) of the animals which 
received day 7 lymph node cells from IL-1 treated animals did not 
develop tumors. This percentage was significantly (p<0.05) higher 
than for animals which received either day 7 lymph node cells from 
non-IL-1 treated animals (0/12 without tumor), or EL-4 alone (0/20 
without tumor). In addition, the animals which received lymph node 
cells from IL-1 treated animals and did develop tumors (75% of the 
total) did so later than animals in the other treatment groups. As 
shown in Table 1, the mean day of tumor appearance was significantly 
later in these animals when compared to animals which received lymph 
node cells from non-IL-1 treated animals (p<0.001) or EL-4 alone 
(p<0.001). 
Adoptive transfer of day 7 lymph node cells from IL-1 treated 
animals also allowed for enhanced animal survival, while cells from 3 
or 5 days post tumor challenge did not (Fig. 4). Animals which 
received cells from IL-1 treated animals exhibited significantly 
(p<0.05) higher total survival when compared to animals which received 
cells from non-IL-1 treated animals or EL-4 alone. The surviving 
animals were immune to a subsequent rechallenge with EL-4. In addi-
tion, the animals which received lymph node cells from IL-1 treated 
animals, but did not survive, lived longer than the animals in the 
other treatment groups. As shown in Table 2, the mean survival in 
days was significantly longer in these animals when compared to 
animals which received lymph node cells from non-IL-1 treated animals 
(p<0.005) or EL-4 alone (p<0.001). These data indicate that lymph 
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Table 1. Effect of day 3, 5, and 7 lymph node cells from IL-1 treated 
and non-IL-1 treated animals on tumor development.a 
----------------------------------------------------------------------
Mean Day of Tumor Appearance 
----------------------------------------------------------------------
Lymph node 
cell source 
(Day) 
3 
5 
7 
EL-4 alone 
11.4 ± 1.9 
(n = 8) 
12.5 ± 2.0 
(n = 8) 
11.2 ± 2.0 
(n = 20) 
Lymph node cells 
from IL-1 treated 
animals 
13.4 ± 1. 7 
(n = 8) 
12.8 ± 0.5 
(n = 8) 
17.3 ± 2.3b 
(n = 20) 
Lymph node cells 
from non-IL-1 
treated animals 
12.0 ± 2.0 
(n = 8) 
12.5 ± 1. 7 
(n = 8) 
13.1 ± 2.lc 
(n = 12) 
----------------------------------------------------------------------
a Lymph node cells were derived from· IL-1 treated and non-IL-1 
treated animals on days 3, 5, and 7 post tumor challenge, and adop-
tively transferred with 5 x 103 EL-4 into naive animals. Animals were 
observed for tumor appearance. Data are expressed as mean values ± 
SD. Twenty-five percent (4/16) of the animals which received day 7 
lymph node cells from the IL-1 treated animals did not develop tumors, 
while all of the animals in the other treatment groups did. The sur-
viving animals were immune to subsequent rechallenge with EL-4. 
b p<0.001, when compared to EL-4 alone. 
p<0.001, when compared to the non-IL-1 treated group. 
c p<0.02, when compared to EL-4 alone. 
Fig. 4. 
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Effect of day 3, 5, and 7 lymph node cells from IL-1 
treated and non-IL-1 treated animals on survival. Lymph 
node cells from IL-1 treated ( • ) and non-IL-1 treated ( A ) 
animals were removed on days 3, 5, and 7 post primary tumor 
challenge. The cells were admixed with 5 x 103 EL-4 in a 
500:1 lymph node cell to EL-4 ratio and were injected in-
tradermally into naive animals (day 3, n = 8 per group; day 
5, n = 8 per group; day 7, n = 20 for EL-4 alone group, n = 
20 for IL-1 group, n = 12 for non-IL-1 group). Tumor 
growth was assessed by the measurement of perpendicular 
diameters. Animals with an average tumor diameter of 
greater than lSmm were considered non-survivors. Animals 
injected with EL-4 alone (0) were assessed also. These 
data represent the same animals shown in Fig. 3., and are 
the summary of 3 experiments. 
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Table 2. Effect of day 3, 5, and 7 lymph node cells from IL-1 treated 
and non-IL-1 treated animals on survival.a 
Lymph node 
cell source 
(Day) 
3 
5 
7 
EL-4 alone 
16.1 ± 2.8 
(n = 8) 
16.0 ± 2.4 
(n = 8) 
14.9 ± 2.4 
(n = 20) 
Mean Animal Survival in Daysb 
Lymph node cells 
from IL-1 treated 
animals 
17.3 ± 2.0 
(n = 8) 
15.8 ± 1.0 
(n = 8) 
20.6 ± 3.8c 
(n = 20) 
Lymph node cells 
from non-IL-1 
treated animals 
17.5 ± 2.5 
(n = 8) 
16.0 ± 1.2 
(n = 8) 
16.8 + 3.8 
(n = 12) 
----------------------------------------------------------------------
a Lymph node cells were derived frotn IL-1 treated and non-IL-1 
treated animals on days 3, 5 and 7 post tumor challenge, and adoptive-
ly transferred with 5 x 103 EL-4 into naive animals. Animals were 
observed for survival. Data are expressed as mean values ± SD. These 
data represent the same animals shown in Table 1. 
b Animals with an average tumor diameter of greater than 15mm were 
considered non-survivors. 
c p<0.001, when compared to EL-4 alone. 
p<0.005, when compared to the non-IL-1 treated group. 
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node cells from IL-1 treated animals were protective against the EL-4 
in vivo, while cells derived from animals which did not receive IL-1 
had no such protective effect. This was evidenced by delayed tumor 
development and enhanced animal survival in animals receiving cells 
from IL-1 treated animals. In addition, protective tumor immunity was 
generated in the surviving animals, in that all of the animals which 
remained free of tumor were also resistant to subsequent tumor chal-
lenge (4/4 animals). 
2. Effect of lymph node cells on average tumor size. 
The tumors which developed in animals receiving adoptively 
transferred cells were measured periodically. As shown in Figure 5, 
there was no difference in average tumor size between IL-1 treatment 
groups for animals receiving lymph node cells from days 3 or 5 post 
tumor challenge. However, the average tumor size of animals receiving 
day 7 lymph node cells from IL-1 treated animals was signifi-cantly 
smaller when compared to animals which received cells from non-IL-1 
treated animals. 
3. Effect of day 7 lymph node and spleen cells on tumor develop-
ment. 
In order to establish whether the capacity to promote in vivo 
effects against EL-4 was a local or systemic immune phenomenon, a com-
parison was made between the ability of adoptively transferred lymph 
node and spleen cells to affect tumor development and animal survival. 
Spleen cells derived 7 days after tumor challenge from either the IL-1 
treated or the non-IL-1 treated animals were unable to affect tumor 
development or animal survival (Fig. 6). As shown in Table 3, animals 
Fig. 5. 
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Effect of day 3, 5, and 7 lymph node cells from IL-1 
treated and non-IL-1 treated animals on average tumor size. 
Lymph node cells from IL-1 treated <•) and non-IL-1 
treated (O) animals were removed on days 3, 5, and 7 post 
primary tumor challenge. The cells were admixed with 5 x 
103 EL-4 in a 500:1 lymph node cell to EL-4 ratio and were 
injected intradermally into naive animals (n = 5 per group 
per day assessed). Tumor growth was assessed by the 
measurement of perpendicular diameters. Data are expressed 
as mean values ± SE. 
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Effect of day 7 lymph node and spleen cells on tumor 
development and animal survival. Lymph node and spleen 
cells from IL-1 treated ( O, {). ) and non-IL-1 treated 
( e , a ) animals were removed on day 7 post primary tumor 
challenge. The cells were admixed with 5 x 103 EL-4 in a 
500:1 lymph node cell to EL-4 ratio and were injected in-
tradermally into naive animals (n = 4 per group for lymph 
node cell assessments, n = 5 per group for spleen cell and 
EL-4 alone assessments). Animals were examined periodi-
cally for the development of tumor (panel A.). Tumor 
growth was assessed by the measurement of perpendicular 
diameters. Animals with an average tumor diameter of 
greater than lSmm were considered non-survivors (panel B.). 
Animals injected with EL-4 alone (•) were assessed as 
well. 
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Table 3. Tumor protection against EL-4 by adoptive transfer of 
lymph node and spleen cells.a 
----------------------------------------------------------------------
Treatment group 
None (n 5) 
Spleen (no IL-1) (n 5) 
Spleen (IL-1) (n = 5) 
Lymph node (no IL-1) (n 4) 
Lymph node (IL-1) (n 4) 
Mean day of tumor 
appearance 
10.0 ± 0.7 
11.8 ± 1.6 
12.0 ± 1.9 
12.8 ± 1.3c 
16.5 ± o. 7d 
Mean survival 
in daysb 
13.8 ± 0.8 
15.6 ± 1.1 
14.4 ± 1.5 
15.5 ± 1. 7 
21.5 ± 0.7e 
a Lymph node and spleen cells derived from IL-1 treated and non-IL-1 
treated animals 7 days after tumor challenge were adoptively trans-
ferred with 5 x 103 EL-4 into naive animals. Animals were observed 
for tumor appearance and survival. Data are expressed as mean values 
± SD. 
b Animals with an average tumor diameter of greater than 15mm were 
considered non-survivors. 
c 
d 
e 
p<0.005, when compared to EL-4 alone. 
p<0.001, when compared to EL-4 alone. 
p<0.05, when compared to spleen (IL-1) group. 
p<0.02, when compared to lymph node (no IL-1) group. 
p<0.001, when compared to EL-4 alone. 
p<0.002, when compared to spleen (IL-1) group. 
p<0.02, when compared to lymph node (no IL-1) group. 
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which received lymph node cells from the IL-1 treated animals (n = 4) 
developed tumors significantly later (p<0.001) and lived significantly 
longer (p<0.001) than animals which received tumor alone (n = 5). In 
addition, the mean day of tumor appearance was later than that ob-
served with animals receiving spleen cells from IL-1 treated animals 
(n = 5, p<0.05). Lymph node cells from the IL-1 treated animals were 
also able to significantly enhance the length of animal survival when 
compared to spleen cells from IL-1 treated animals (p<0.002). Animals 
which received spleen cells from the IL-1 treated animals did not 
exhibit significantly later tumor development or enhanced survival 
when compared to animals from the other treatment groups. These data 
indicate that, within the time period examined, the ability of lym-
phoid cells from IL-1 treated animals to delay tumor development and 
enhance animal survival was present in the draining lymph nodes and 
was not a systemic phenomenon involving the spleen. 
4. Effect of various cell populations on tumor development and 
animal survival. 
Depletion of CD4+, cos+, or asial~ GMl+ cells affected the 
ability of lymph node cells from IL-1 treated animals to mediate an-
titumor effects. Antitumor effects were assessed by measuring tumor 
development and animal survival in adoptive transfer assays (-CD4+, n 
= 3; -cos+, n = 3; -asialo GMl, n = 4). Lymph node cells depleted of 
any of the cell populations were unable to prevent tumor development, 
although the time of tumor appearance was later than in the animals 
which received tumor alone (Fig. 7). In contrast, lymph node cells 
which were treated with complement alone were able to delay tumor 
Fig. 7. 
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Effect of lymph node cell population depletion on tumor 
development and animal survival. Lymph nodes from IL-1 
treated and non-IL-1 treated animals were removed on day 7 
post primary tumor challenge. Lymph node cells from the 
IL-1 treated animals were depleted of CD4+ (• ), coa+ (A), 
or asialo GMl+ (A) cells by treatment with specific an-
tibody and complement. In addition, lymph node cells from 
IL-1 treated (O) and non-IL-1 treated ( O) animals were 
treated with complement alone. The cells were admixed with 
5 x 103 EL-4 in a 500:1 lymph node cell to EL-4 ratio and 
were injected intradermally into naive animals (-CD4+, n = 
3; -cna+, n = 3; -asialo GMl+, n = 4; IL-1 complement-
treated, n = 4; non-IL-1 complement treated, n = 4; EL-4 
alone, n = 5). Animals were examined periodically for the 
development of tumors (panel A.). Tumor growth was as-
sessed by the measurement of perpendicular diameters. 
Animals with an average tumor diameter of greater than 15mm 
were considered non-survivors'(panel B.). Animals injected 
with EL-4 alone (•>were assessed as well. 
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50 
development, and to prevent tumors in 50% of the animals. 
An assessment was made of the relative ability of co4+ and cos+ 
lymph node cell populations from IL-1 treated and non-IL-1 treated 
animals to mediate effects against EL-4 in naive animals. CD4+ 
populations were isolated from lymph nodes of IL-1 treated and non-IL-
1 treated animals. These cells were combined with cos+ lymph node 
cells (as described in Fig. S), and adoptively transferred with EL-4 
into naive animals [C04+ (IL-1) +cos+ (IL-1), n = 5; CD4+ (IL-1) + 
cos+ (no IL-1), n = 4; C04+ (no IL-1) +cos+ (no IL-1), n = 5). 
Delayed tumor development was observed when both the co4+ cells and 
the cos+ cells were from the IL-1 treated animals. As shown in Table 
4, animals which received recombined cells from IL-1 treated animals 
developed tumors significantly (p<0.02) later than animals which 
received EL-4 alone. In addition, these animals showed enhanced sur-
vival (p<0.02) when compared to the EL-4 alone animals. However, no 
significant differences were observed when a direct comparison was 
made between animals which received co4+ and cos+ cells from IL-1 
treated animals and animals which recei~ed co4+ and cos+ cells from 
non-IL-1 treated animals. Adoptive transfer of C04+ and cos+ cell 
populations was not as effective as whole lymph node cell populations 
in promoting animal survival (no animals survived beyond 25 days). 
When both the co4+ cells and the cos+ cells were from non-IL-1 treated 
animals, no significant delay in tumor development or increase in 
animal survival was observed when compared to animals injected with 
EL-4 alone. These data suggest that C04+ and/or COS+ cells may be in-
volved in the tumor protective effects observed in the adoptive trans-
Fig. S. 
51 
Effect of recombined lymph node cell populations on tumor 
development and animal survival. Lymph nodes from IL-1 
treated and non-IL-1 treated animals were removed on day 7 
post primary tumor challenge. C04+ and cos+ cell popula-
tions were obtained by negative selection with specific 
antibody and complement treatment. These populations were 
recombined in the following manner: co4+ (IL-1) + cos+ (IL-
1); co4+ (IL-1) +cos+ (no IL-1); and co4+ (no IL-1) +cos+ 
(no IL-1). The cells were admixed with 5 x 103 EL-4 in a 
500:1 lymph node cell to EL-4 ratio and were injected in-
tradermally into naive animals [C04+ (IL-1) +cos+ (IL-1), 
n = 5; C04+ (IL-1) +COS+ (no IL-1), n = 4; C04+ (no IL-1) 
+COS+ (no IL-1), n =SJ. Animals were examined periodi-
cally for the development of tumor (panel A.). Tumor 
growth was assessed by the measurement of perpendicular 
diameters. Animals with an average tumor diameter of 
greater than lSmm were considered non-survivors (panel B.). 
Animals injected with EL-4 alone (O, n = 4) were assessed 
also. 
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Table 4. Tumor protection against EL-4 by adoptive transfer of 
recombined lymph node cell populations to naive animals.a 
Treatment group 
None (n 5) 
CD4+ (IL-1) 
cos+ (IL-1) (n 5) 
CD4+ (IL-1) 
cos+ (no IL-1) (n = 4) 
CD4+ (no IL-1) 
cos+ (no IL-1) (n = 5) 
Mean day of tumor 
appearance 
11.4 ± l.9 
lS.2 ± 4.3c 
15.0 ± 2.9 
12.4 ± 2.0 
Mean survival 
in daysb 
15.0 ± l.S 
23.4 ± 5.2c 
20.3 ± 3.6d 
19.4 ± 4.3 
----------------------------------------------------------------------
a Negatively selected lymph node cell populations from IL-1 treated 
and non-IL-1 treated animals were recombined and adoptively trans-
ferred with 5 x 103 EL-4 into naive animals. Animals were observed 
for tumor appearance and survival. Data are expressed as mean values 
± SD. 
b Animals with an average tumor diameter of greater than 15mm were 
considered non-survivors. 
c p<0.02, when compared to EL-4 alone. 
d p<0.05, when compared to EL-4 alone. 
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fer assays. In summary, the adoptive transfer assay data demonstrate 
the ability of lymph node cells from IL-1 treated animals to mediate 
tumor protective effects in vivo as evidenced by delayed tumor de-
velopment, enhanced animal survival, and generation of protective 
immunity in surviving animals. 
o. Effect of IL-1 treatment on IL-2 responsiveness of lymph node 
cells. 
The preceding experiments established the ability of lymph node 
cells from IL-1 treated animals to mediate responsiveness to EL-4. A 
series of experiments was performed to assess the effects of systemic 
IL-1 therapy on the local immune parameters of lympho-proliferation 
and cytotoxic potential. Enhanced responsiveness to IL-2 could lead 
to the expansion of cell populations important in tumor survival and 
the generation of immunity (Izumi et al., 1985; North et al., 1988). 
In the IL-1 treatment groups, lymph node cell numbers were increased 
on days 3, 4 and 5 post primary tumor challenge (Fig. 1). Therefore 
these lymph node cells were assessed for their capacity to respond to 
IL-2. As shown in Figure 9, lymph node cells from the IL-1 treated 
animals had greater proliferative capacity in response to IL-2. The 
day 3 lymph node cells from the IL-1 treated animals showed a greater 
proliferative ability after 5, 6, and 7 days in IL-2 (p<0.01, p<0.001, 
p<0.001) as compared to the non-IL-1 treated animals. The day 4 cells 
showed a lower degree of proliferation than the day 3 cells. The day 
5 lymph node cells also showed a lower proliferative ability when 
compared to day 3 cells, but the differences between IL-1 and non-IL-1 
treated groups were significant after all three culture periods in IL-
Fig. 9. 
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Effect of IL-1 treatment on IL-2 responsiveness of lymph 
node cells. Lymph node cells from IL-1 treated (W) and 
non-IL-1 treated (D) animals were stimulated with 1500 U 
IL-2/ml for 5, 6 or 7 days. Proliferation was assessed by 
incorporation of [ 3H]thymidine, and the stimulation indices 
determined. The stimulation index is equal to the radioac-
tivity incorporation of cells stimulated with IL-2, divided 
by the radioactivity incorporation of cells without IL-2. 
Assessments were performed in triplicate on lymph node 
cells pooled from 15 animals per group. Data are expressed 
as the mean value ± SE. 
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2 (p<0.001, p<0.001, p<0.02). Peak proliferative responses were ob-
served after 5 days of stimulation with IL-2. 
In addition, lymph node cells from IL-1 treated and non-IL-1 
treated animals were evaluated to determine if the enhanced IL-2 
responsiveness in the IL-1 treated animals could lead to increased 
cell numbers following IL-2 stimulation in vitro. Although the direct 
number of recoverable cells was similar in both treatment groups 
(Table 5), the total number of recoverable cells in the IL-1 treated 
animals was significantly higher on four of the five days tested (Fig. 
10). These data indicate that systemic IL-1 treatment in vivo en-
hanced lymph node cell responsiveness to IL-2 in vitro. 
E. IL-1 effects on cytotoxic ability of lymph node cells. 
1. Effect of IL-1 treatment on cytotoxic potential of lymph node 
cells. 
The next series of experiments was performed to determine if 
systemic IL-1 treatment enhances the cytotoxic ability or potential of 
draining lymph node cells. When first removed from the animal, lymph 
node cells from both IL-1 treated and non-IL-1 treated animals showed 
little or no cytotoxic activity against EL-4, YAC-1, or P815. Lytic 
activities were less than 10 lytic units/107 cells at 30% lysis for 
all targets tested, regardless of the treatment group (data not 
shown). Following stimulation with IL-2, however, cytotoxic activity 
was observed against both natural killer cell (NK)-sensitive (YAC-1) 
and NK-resistant (EL-4, P815) tumor cells. 
Lymph node cells from IL-1 treated and non-IL-1 treated animals 
were stimulated with IL-2 for 7 days, and assessed for cytotoxic ac-
Fig. 10. 
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Effect of IL-1 treatment on the number of recoverable cells 
following IL-2 stimulation. Triplicate cultures of lymph 
node cells from IL-1 treated (QO) and non-IL-1 treated (Cl) 
animals were stimulated with 1500 U IL-2/ml for 7 days. 
Viable cells were isolated and the percent recovery deter-
mined. The percent recovery equals the number of viable 
cells, divided by the number of cells placed in culture, 
multiplied by 100. These percentages were multiplied by 
the lymph node cell number to obtain the total number of 
recoverable cells/animal. Data points represent the mean 
of 3 groups of 5 animals each and are expressed as the mean 
value ± SE. 
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Table 5. Effect of IL-1 treatment on lymph node cell number and 
Day 
3 
4 
5 
6 
7 
the number of recoverable cells following IL-2 stimulation. 
Lymph node cell numbera 
(cell number x 10-6) 
Treatment group 
IL-1 no IL-1 
13.1 ± 0.9 7.1 ± 1.0 
18.0 ± 0.7 10.1 ± 1. 7 
17.3 ± 0.7 14.1 ± 0.7 
16.6 ± 0.4 14.7 ± 1.6 
9.9 ± 0.8 4.9 ± 0.6 
Recoverable cells per 5 x 106 
cells stimulated with IL-2b 
(cell number x 10-6) 
Treatment group 
IL-1 no IL-1 
1.08 ± 0.20 0.99 ± 0.47 
1.46 ± 0.17 1.16 ± 0.16 
1.31 ± 0.21 1.22 ± 0.23 
1. 73 ± 0.45 1.54 ± 0.14 
3.13 ± 0.45 3.31 ± 0.30 
----------------------------------------------------------------------
a Lymph node cell numbers represent values depicted in Fig. 1. Data 
are expressed as mean values ± SE and represent the mean of 3 groups 
of 5 animals each, per treatment group, per day post tumor challenge. 
b Lymph node cells were stimulated with IL-2 as described in Fig. 10. 
Data are expressed as the number of cells recovered per 5 x 106 lymph 
node cells stimulated. 
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tivity against EL-4, YAC-1, and P815 (a representative experiment is 
shown in Table 6). While reactivity was generated in both the IL-1 
treated and non-IL-1 treated groups, the IL-1 treated group showed the 
greatest enhancement in terms of lytic units of activity per axillary 
and brachia! lymph node (Fig. 11). This activity varied depending on 
the time at which lymph node cells were obtained post tumor challenge 
and appeared to be a function of the increase in lymph node cell num-
ber seen in the IL-1 treated animals. Significantly higher cytotox-
icity was observed in the IL-1 treated animals on days 4 through 6 
post tumor challenge for EL-4 and YAC-1, and days 3 through 7 for 
P815. Total activity was highest against the NK-sensitive target for 
both treatment groups. These data indicate that IL-1 treated animals 
had a greater capacity to develop cytotoxic activity against a variety 
of tumor targets, and suggest that a heterogenous population of effec-
tors may be generated by IL-2 stimulation. 
2. Effect of IL-1 treatment on cytotoxic cell freguency. 
The enhanced in vitro cytotoxic capability of the IL-2 stimu-
; 
lated lymph node cells (from the IL-1 treated animals) may be due to a 
greater number of IL-2 inducible cytotoxic cells in the lymph nodes of 
IL-1 treated animals. In order to assess this possibility, limiting 
dilution analysis was performed. Lymph node cells were harvested on 
sequential days following primary tumor challenge (10 animals per 
treatment group, per day. Figure 12 shows the cytotoxic cell precur-
sor frequencies for bra-chial and axillary lymph node cells derived 
days 1 through 4 post tumor challenge. Each panel depicts the cyto-
toxic cell frequency for an individual day post tumor challenge. Lit-
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Table 6. Effect of IL-1 treatment on lytic activity of IL-2 
stimulated lymph node cells.a 
IL-1 treated animals non-IL-1 treated animals 
Tumor target Tumor target 
Day EL-4 YAC-1 P815 EL-4 YAC-1 P815 
3 74 64 17 135 64 
4 10 84 24 10 22 10 
5 10 204 88 10 100 47 
6 48 247 124 28 161 121 
7 10 165 108 16 177 90 
a Lymph node cells were stimulated with IL-2 as described in Fig. 10. 
After 7 days, the cells were assessed for their cytotoxic activity 
against EL-4, YAC-1, and P815 in a 4 hour chromium release assay with 
effector to target ratios ranging from 50:1 to 6:1. Linear regression 
analysis was used to determine the lytic unit activity. 
b Data are expressed as lytic units/107 cells at 30% lysis, and are 
from a representative experiment. 
Fig. 11. 
63 
Effect of IL-1 treatment on cytotoxic potential of lymph 
node cells. Lymph node cells from IL-1 treated (Bl) and 
non-IL-1 treated (0) animals were stimulated with IL-2 as 
in Figure 10. After 7 days, the cells were assessed for 
their cytotoxic activity against EL-4, YAC-1, and P815 in a 
4 hour chromium release assay with effector to target 
ratios ranging from 50:1 to 6:1. Linear regression 
analysis was used to determine the number of lytic 
units/107 cells at 30% lysis. These values were multiplied 
by the recoverable cell numbers from Figure 10 to obtain 
the number of lytic units per animal. Data points 
represent the mean of three groups of five animals each and 
are expressed as the mean value ± SE. 
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Cytotoxic cell frequency analysis of day 1-4 lymph node 
cells. Limiting dilution analysis was performed on lymph 
node cells from IL-1 treated ( e , •, •; n = 10 animals per 
day) and non-IL-1 treated ( o , 4, a; n = 10 animals per 
day) animals. Various numbers of lymph node cells were 
cultured with 120 U/well (800 U/ml) of IL-2. After 7 days, 
the cells were assessed for cytotoxic activity by the addi-
tion of chromium-labeled tumor targets. Both NK sensitive 
(YAC-1) and NK resistant (EL-4, P815) tumor targets were 
used. Positive wells were those with chromium release 
greater than 3 SD above spontaneous release. The data is 
presented as the fraction of wells which failed to develop 
lytic activity versus the number of lymph node cells/well. 
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tle cytotoxic activity was noted on day 1 for any of the tumor tar-
gets, regardless of the therapeutic protocol. By day 2, the potential 
for activity against YAC-1 developed in the IL-1 treated group. Day 3 
lymph node cells from the IL-1 treated group demonstrated the ability 
to develop activity against all three tumor targets, while cells from 
the non-IL-1 treated group had no detectable cytolytic cell activity. 
By day 4 the potential for activity against YAC-1 was present in the 
non-IL-1 treated group. In Figure 13, the cell frequencies for days 5 
through 7 post tumor challenge are depicted. Lymphoid cytotoxic ac-
tivity for days 5 through 7 showed a decrease in frequency for the IL-
1 treated group and an increase for the non-IL-1 treated group. Day 5 
and 6 lymph node cells from the non-IL-1 treated group showed the 
potential to develop activity against YAC-1, and to a lesser extent 
against EL-4. By day 7 post tumor challenge neither group displayed 
the potential to develop cytotoxic activity. No difference in ac-
tivity between groups was noted after day 6. 
The cytolytic cell frequencies derived from the frequency graphs 
are summarized in Table 7. The 95% confidence levels obtained from 
the minimum chi-square analysis (Taswell, 1981) revealed a significant 
increase in cytolytic cell frequency in the lymph node cells of IL-1 
treated animals on days 2 and 3, for all tumor targets tested, when 
compared to cells from the non-IL-1 treated group. On day 4, the 
frequency of cytolytic cells with activity against EL-4 and P815 was 
significantly higher in the IL-1 treated group. However, the fre-
quency of cytolytic cells with activity against YAC-1 was similar in 
the IL-1 treated and non-IL-1 treated animals. By 5 days after tumor 
Fig. 13. 
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Cytotoxic cell frequency analysis of day 5-7 lymph node 
cells. Limiting dilution analysis was performed on lymph 
node cells from IL-1 treated ( • , A , • ; n = 10 animals per 
day) and non-IL-1 treated ( o, A , o; n = 10 animals per 
day) animals as in Figure 12. Positive wells were those 
with chromium release greater than 3 SD above the spon-
taneous release. 
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Table 7. IL-2 inducible lymph node cytolytic cell frequencies 
for various tumor targets.a 
IL-1 treated animals non-IL-1 treated animals 
Tumor target Tumor target 
----------------------- -----------------------
Day EL-4 YAC-1 P815 EL-4 YAC-1 P815 
-------------------------------------------------------------------
1 n.d. b n.d. n.d. n.d. n.d. n.d. 
2 n.d. 1/34000c 1/83000c n.d. n.d. n.d. 
3 1/47000c 1/35000c 1/52000c n.d. n.d. n.d. 
4 1/34000c 1/25000 1/86000c n.d. 1/65000 n.d. 
5 n.d. 1/103000 n.d. 1/60000c 1/34000c n.d. 
6 1/155000 1/164000 n.d. 1/103000 1/150000 n.d. 
7 n.d. n.d. n.d. n.d. n.d. n.d. 
a Limiting dilution analysis was performed as described in Figure 12. 
Frequencies are expressed as cytolytic cell frequency/number of lymph 
node cells. Statistical significance was determined by 95% confidence 
limits of the minimal chi-square analysis. Data represent pooled 
lymph node cell populations from 10 animals per treatment group, per 
day post tumor challenge. 
b none detected. 
c p<0.05, when compared to frequency against same target cell in the 
other treatment group. 
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challenge, the non-IL-1 treated animals had a significantly higher 
frequency of cytolytic cells with activity against YAC-1 and EL-4 when 
compared to the IL-1 treated animals. 
In order to demonstrate the temporal difference in cytotoxic 
cell development between IL-1 treated and non-IL-1 treated animals, 
the cell frequency data were alternatively analyzed and the percentage 
of positive scoring wells for one particular cell dilution (5 x 104 
lymph node cells) depicted (Fig. 14). When compared to cells from the 
non-IL-1 treated animals, lymph node cells from the IL-1 treated 
animals demonstrated an earlier, augmented development of cytotoxic 
activity. A more modest response was observed in animals which re-
ceived 200 U per injection of IL-1. For example, activity against EL-
4 developed on day 3 for the 500 U IL-1 group, on day 4 for the 200 U 
IL-1 group, and on day 5 for the non-IL-1 treated group. Similarly, 
the potential for maximal activity against YAC-1 was observed on days 
2 through 4 for the 500 U IL-1 group, day 4 for the 200 U IL-1 group, 
and day 5 for the non-IL-1 treated group. These data indicate that in 
/ 
vivo systemic IL-1 treatment enhanced the capacity to induce total 
lymph node cytotoxic activity in vitro as assessed by enhanced cyto-
toxic activity and increased cytotoxic cell frequency. 
Maximal cytotoxic cell frequencies in the limiting dilution 
assay occurred with lymph node cells derived before day 6, with vari-
able cytotoxic activity depending upon the treatment group from which 
the cells were derived. In contrast, maximal cytolytic activity in 
the bulk-cultured cells was observed with lymph node cells derived 6 
days post tumor challenge (Table 6), and cytotoxicity against all 
Fig. 14. 
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Relationship of IL-1 dose to cytotoxic cell frequency. The 
percentage of positive wells for a single cell concentra-
tion (5 x 104 lymph node cells/well) was determined using 
limiting dilution analysis. Data shown are for animals 
treated with 0 ( O ) , 200 ( • ) , and 500 ( e ) U IL-1/injec-
tion and represent the same animals as Fig. 12 and 13. In-
dividual panels represent the data for EL-4, YAC-1 and P815 
tumor targets. 
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three tumor targets was generated regardless of the treatment group. 
F. Antigenic responsiveness. 
Because the protective immunity generated in this system is 
tumor-specific (Hornung and Mathews, unpublished observation), it may 
be hypothesized that animals receiving IL-1 therapy develop reactivity 
to EL-4. In accordance with the enhanced local responsiveness 
demonstrated above, it could be suggested that this reactivity may be 
found in the local lymph nodes. Therefore, the ability of lymph node 
cells from IL-1 treated animals to proliferate in vitro in response to 
stimulation with EL-4 was assessed in an antigenic responsiveness 
assay. Briefly, animals which survived primary tumor challenge (with 
or without IL-1 therapy) were rechallenged in vivo with either EL-4 or 
the unrelated tumor LLC (n = 5 animals per group, per day; 40 total). 
The rechallenge served to increase the number of cells in the lymph 
nodes and therefore to enable multiple assessments of activity. Lymph 
node cells were removed from these animals at various times post 
rechallenge and stimulated in vitro with EL-4 or LLC. As shown in 
Figure 15, only the animals which receiv~d systemic IL-1 therapy at 
the time of primary tumor challenge were able to respond to EL-4 
stimulation in vitro (panel A.). This responsiveness was observed 14 
days after secondary tumor challenge, and was significantly higher 
(p<0.001) than that elicited by LLC in vitro. Animals which did not 
receive IL-1 therapy at the time of primary tumor challenge did not 
demonstrate enhanced responsiveness to EL-4 (panel C.) Lymph node 
cells from animals which received adjuvant and IL-1 therapy, but were 
rechallenged with LLC in vivo (panel B.), also did not show an en-
Fig. 15. 
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Effect of IL-1 treatment on tumor-specific lymph node cell 
proliferation in secondary challenge animals. Animals 
which survived primary tumor challenge with either IL-1 and 
adjuvant therapy, or adjuvant therapy alone, were rechal-
lenged on the opposite flank with either EL-4 or the unre-
lated tumor LLC (n = 5 animals per treatment group, per 
day). On various days post secondary challenge, the lymph 
nodes draining the site of tumor rechallenge were removed. 
Cells were stimulated in culture for 7 days with either 
mitomycin c treated EL-4 ( 121) or LLC (a). Tumor-specific 
stimulation was assessed by the incorporation of [ 3H]thymi-
dine in a 6 hr assay. Data are expressed as mean stimula-
tion indices ± SE. 
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hanced proliferative response. Animals which did not receive IL-1 
therapy (panel D.) showed little responsiveness to EL-4 or LLC in 
vitro, following in vivo rechallenge with LLC. These data demonstrate 
that lymph node cells from IL-1 treated animals were able to 
proliferate in response to EL-4 stimulation. This responsiveness was 
predominantly tumor-specific as shown by the low level of prolifera-
tion in response to LLC in vitro. No such lymphoproliferation was 
observed in animals undergoing primary tumor challenge (data not shown). 
CHAPTER V 
DISCUSSION 
In recent years, the use of biological response modifiers in the 
treatment of cancer has been evaluated in both animal tumor systems 
and clinical trials. The use of immunotherapy has been proposed as an 
adjunct to more traditional forms of therapy such as surgery, radio-
therapy, and chemotherapy. In this way, the immune-enhancing effects 
of various cytokines may work in concert with the direct anti-cancer 
activities of the other treatments. IL-1 may be useful as a im-
munotherapeutic mediator because of its multiple effects upon immune 
cells. IL-1 has a number of effects upon T and B lymphocyte function, 
as well as on macrophages and NK cells. These effects include enhan-
cement of antibody secretion (Wood, 1979), T lymphocyte proliferation 
(Smith, 1980), and macrophage cytotoxicity (Onozaki et al., 1985a). 
As an activating factor for T cells (Larsson et al., 1980), IL-1 in-
duces IL-2 production and therefore augments the generation of helper 
and cytolytic T-lymphocytes (Koopman et al., 1978; Farrar et al., 
1980; McMannis and Plate, 1985). IL-1 synergizes with IL-2 in the 
generation of lymphokine activated killer (LAK) cells in vitro (Crump 
et al., 1989). IL-1 is directly cytocidal for certain tumor cell 
lines (Onozaki et al., 1985b) and in high doses can promote tumor 
regression in some tumor model systems (Nakamura et al., 1986). In 
vivo administration of IL-1 can restore impaired T cell and NK cell 
functions in tumor-bearing mice (Yamashita and Shirakawa, 1987). 
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The general enhancement of immune function seen with IL-1 
treatment may make it valuable as a therapeutic modality in tumor 
therapy in conjunction with other therapies. Although other inves-
tigators have demonstrated the efficacy of IL-1 in promoting host 
survival of tumor inoculation (Nakamura et al., 1986; North et al., 
1988; McCune and Marquis, 1990), little is known about the IL-1 ef-
fects which may lead to host protection. One of the drawbacks to the 
use of cytokines in immunotherapy is the lack of knowledge about their 
in vivo effects. Little is known about the immunoregulatory effects 
of IL-1 in vivo. In addition, many of the in vivo studies of IL-1 ef-
fects in experimental tumor models require high doses of IL-1 to 
produce an antitumor effect (Nakamura et al., 1986; North et al., 
1988). In the experimental model under investigation, low dose in-
traperitoneal IL-1 therapy results in a protective tumor immunity 
(Hornung and Mathews, 1985). The amount of IL-1, although low, was 
sufficient to affect immune parameters resulting in subsequent tumor 
protection. The apparent tumor immunity was specific to the initial 
tumor and not to another syngeneic tumor (Hornung and Mathews, un-
published observations). This experimental model was selected for 
further investigation because low doses of IL-1 promoted immunity when 
administered in conjunction with adjuvant therapy. 
Using this experimental model, a series of in vitro experiments 
were performed to assess EL-4 reactive antibody titers, natural killer 
cell activity, and EL-4 cytotoxic T cell activity in animals under-
going secondary tumor challenge (Hornung, dissertation, 1987). These 
animals had received EL-4 and local adjuvant (~. parvum) therapy or 
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EL-4 and adjuvant plus IL-1 at the time of primary tumor challenge. 
Little or no cytotoxic T cell activity against the EL-4 was detected 
in the spleens of either the IL-1 treated or non-IL-1 treated animals. 
The spleen cell populations from the two treatment groups showed no 
apparent difference in natural killer cell activity. In addition, no 
increase in antibody titer was detected in the sera of animals from 
either treatment group. The IL-1 treated animals showed no augmenta-
tion in the immune parameters measured. 
Although not demonstrated directly in the previous study, it is 
possible that IL-1 plays a role in the modulation of the immune re-
sponse to the EL-4 lymphoma and that this modulation affects the gen-
eration of tumor immunity. The objective of this study was to inves-
tigate the nature of the local lymphoid responsiveness generated by 
IL-1 treatment and evaluate the relationship between this lymphoid 
responsiveness and the induction of tumor immunity in this ex-
perimental model. This model was selected because the tumor is re-
sponsive to adjuvant therapy, and IL-1 treatment allows for the gen-
eration of apparent tumor-specific immunity to a weakly immunogenic 
tumor. 
Because IL-1 therapy is administered only at the time of initial 
tumor challenge, an evaluation was made of IL-1 treated and non-IL-1 
treated animals undergoing primary tumor challenge. A careful as-
sessment of the immune status of animals undergoing primary tumor 
challenge has not been made previously. These experiments were per-
formed to determine whether systemic IL-1 could modify local immune 
responses in animals undergoing adjuvant therapy for a primary tumor. 
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These investigations revealed that systemic administration of IL-1 
results in enhanced immune responsiveness in the lymph nodes draining 
the site of tumor challenge. The systemic administration of IL-1 aug-
mented local lymphoid responsiveness as demonstrated by increased 
lymph node cell number, enhanced numbers of T lymphocytes, and in-
creased total cytotoxic potential (Fig. 1, 2, 11-14). 
The reasons for examining local responses in this system were 
two-fold: first, little systemic enhancement of immune function has 
been noted previously (Hornung, dissertation, 1987), secondly, it has 
been shown that regional lymph nodes play an important role in the 
host response to disease and tumors. Stephenson et al. (1989) ex-
amined the role of regional lymph nodes in the tumor immune response. 
They inoculated mice with a mixture of viable tumor cells and ~· par-
vum, and excised the regional lymph nodes on various days post tumor 
challenge. The development of systemic immunity was severely impaired 
if regional lymph nodes were excised on day 6 post tumor challenge, 
but excision of the lymph nodes on day 14 had no impact on the de-
velopment of systemic immunity. Therefore, essential lymph node 
events in the development of systemic immunity occur early after tumor 
challenge. In the current investigation, enhancement of immune para-
meters in the IL-1 treated animals occurred soon after primary tumor 
challenge. By 3 days post tumor challenge, increases in total cell 
number and T lymphocytes, as well as enhanced proliferative abilities 
and cytotoxic potential were observed. By day 7, lymph node cells 
showed enhanced abilities to modify responses to EL-4 in naive ani-
mals. 
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Other investigators have found a correlation between the degree 
of lymph node swelling and the amount of antigen administered (Zatz 
and Lance, 1971). Increased lymph node size due to the accumulation 
of lymphocytes has been associated with enhanced responsiveness to 
antigen, and may be the mechanism of action of some adjuvants (Dresser 
et al., 1970; Frost and Lance, 1978). Increases in lymph node cell 
number could lead to increases in the numbers of cells available to 
react to the tumor. EL-4 alone produces no increase in the number of 
lymph node cells (Hornung and Mathews, 1985). Administration of IL-1 
produced an early increase in the number of lymph node cells draining 
the site of tumor challenge (Fig. 1). This increase was statistically 
significant when compared with animals which received adjuvant therapy 
without IL-1. The expansion in cell number in the IL-1 treated 
animals may represent an expansion of cell populations relevant to the 
immune response to the tumor. The cell number increase may represent 
a generalized immune augmentation which allows for sufficient in-
creases in specific populations. IL-1 treatment may convert a sub-
therapeutic number of sensitized T cells to a therapeutic number by 
stimulating an increase in the production of sensitized cells (North 
et al., 1988). In animals which received adjuvant therapy without IL-
1, the cell number increase was smaller and was temporally delayed 
when compared to IL-1 treated animals. 
Phenotypic analysis of the lymph node cells in the EL-4 tumor 
system revealed an overall increase in T lymphocytes, and T lymphocyte 
subsets in the IL-1 treated animals. Enhanced numbers of Thy 1.2+ 
lymphocytes were present in the IL-1 treated animals on days 3 and 4 
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post tumor challenge. Approximately 80 to 85% of the cell number 
increase could be accounted for by the increase in Thy 1.2+ lympho-
cytes. The cell number increase may reflect an increased localization 
of antigen-reactive cells. The increase in Thy 1.2+ lymphocytes was 
composed of increases in either co4+ or CD8+ cells, and therefore 
indicates an overall augmentation of cell number by IL-1 treatment. 
In an immunogenic tumor model, the efficacy of IL-1 therapy has been 
shown to be dependent upon an underlying host immune response (North 
et al., 1988). These authors suggest that IL-1 acts in vivo by aug-
menting an already ongoing immune response, and therefore can cause 
the regression of tumors of sufficient immunogenicity. In several 
tumor models, concomitant immunity develops as the tumor grows; how-
ever, this response is insufficient to prevent the progressive growth 
of the tumor and subsequent animal mortality. North et al. (1988) 
have demonstrated that systemic IL-1 treatment can augment this immune 
response to a level sufficient to cause tumor regression and host 
survival. In the current study, IL-1 non-specifically augments the 
' 
number of lymph node cells. This may increase a low level of respon-
siveness to the EL-4 to an amount above the threshold necessary for 
the development of tumor immunity. This effect has not been demon-
strated previously in a weakly immunogenic tumor system. 
The cell number increase generated by IL-1 therapy was 
predominantly T cell in nature. In contrast, other in vivo studies 
have shown an IL-1 induced effect on B lymphocytes. Killar et al. 
(1989) administered 2000 to 5000 U of IL-1 systemically on a daily 
basis in a non-antigen driven system. They found that IL-1 therapy 
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increased the size of lymph nodes draining the IL-1 injection site, as 
well as the yield of mononuclear cells. A five-fold increase in cell 
number was seen in the IL-1 treated animals. The IL-1 treated lymph 
node cells showed a reduction in the proportion of Thy l+ cells, with 
a concomitant increase in surface immunoglobulin expressing cells. 
The percentage of Thy l+ cells fell from 81% in the control animals to 
38% in the IL-1 treated, while the percentage of surface immuno-
globulin expressing cells rose from 18% to 46%. Decreases in CD4 and 
CDS expression were also noted. Those authors concluded that the 
increase in B cells was due to IL-1 induced production of IL-4, IL-2, 
and interferon gamma by CD4+ cells in the lymph nodes. 
In contrast, IL-1 adminstration in the EL-4 tumor system did not 
reduce the percentage of T cell marker expressing cells, and actually 
increased total Thy l+ cell numbers (Fig. 2). In the system used by 
Killar et al. (1989), no antigen or adjuvant was administered with the 
IL-1. The presence of antigen and the adjuvant g. parvum in the EL-4 
system may affect lymphocyte trafficking and therefore increase T 
lymphocyte cell numbers. T cell numbers could also be increased by 
the development of a T cell response to antigenic determinants of the 
tumor. In addition, g. parvum has been shown to enhance T cell re-
sponsiveness (Tuttle and North, 1976), and may function to stimulate T 
cell-mediated immunity. Dye et al. (1981) determined that the thera-
peutic effect of g. parvum in an immunogenic tumor system was based on 
the capacity to potentiate the generation of T cell-mediated immunity. 
The g. parvum induced antitumor resistance resulted in the generation 
of T cells sensitized to tumor-specific transplantation antigens. 
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Mills et al. (1981) proposed that Q. parvum acts by augmenting the 
host response to the tumor to a level sufficient to cause tumor re-
gression. In the weakly immunogenic EL-4 tumor model, Q. parvum ther-
apy is sufficient to allow for primary tumor survival, but not the 
development of subsequent tumor immunity (Hornung and Mathews, 1985; 
Hornung, dissertation, 1987). IL-1 may promote tumor immunity by 
further potentiating the T cell immunity generated by adjuvant therapy 
with Q. parvum. 
Utilizing adoptive transfer of tumor resistance as an assay of 
in vivo activity, experiments were performed to assess the ability of 
IL-1 treatment to modify the tumor-protective properties of regional 
lymphoid tissue. These experiments showed that lymph node cells from 
IL-1 treated animals have the potential to mediate effects against EL-
4 in vivo as demonstrated by delayed tumor development and enhanced 
animal survival. Lymph node cells from IL-1 treated animals were 
unique in their ability to adoptively modify responses to EL-4 in 
naive animals. Cells derived 7 (but not 3 or 5) days post tumor chal-
lenge were capable of mediating this effect (Fig. 3, 4). Animals 
which received lymph node cells from the IL-1 treated animals demon-
strated delayed tumor development and enhanced survival (Table 1, 2). 
In addition, the animals which survived tumor challenge were immune to 
EL-4 upon subsequent rechallenge. When these animals were subsequent-
ly challenged with the unrelated tumor LLC, they did not survive. 
Therefore, lymph node cells from IL-1 treated animals not only modi-
fied responsiveness to EL-4 in naive animals, but also allowed for the 
development of tumor-specific immunity in some animals. 
S6 
As shown in Fig. 7, depletion of CD4+, CDS+, or asialo GMl+ 
populations reduced the effectiveness of the adoptively transferred 
cells. Reductions in the ability of the cells to delay tumor devel-
opment and to promote animal survival were seen. In recombination 
experiments, CD4+ and cos+ cells from IL-1 treated animals performed 
better than either co4+ and cos+ cells from non-IL-1 treated animals, 
or CD4+ from IL-1 treated and CDS+ from non-IL-1 treated animals (Fig. 
S, Table 4), although statistically significant differences were not 
seen. These results are consistent with the suggestion that both 
helper (CD4+) and cytotoxic (CDS+) populations may be relevant to the 
antitumor effect of adoptively transferred cells (Crum, 1982). Spleen 
cells from the IL-1 treated animals were unable to affect responses to 
the tumor (Fig. 6, Table 3). The inability of spleen cells from day 7 
post challenge animals to mediate effects against EL-4 indicates that 
IL-1 acts upon local lymphoid populations in the time frame examined. 
These data support the hypothesis that local immune responsiveness is 
modified by IL-1 induced effects in this experimental tumor model. 
In the current investigation, lymphocytes were effective in 
adoptive transfer assays when used directly after removal from the 
tumor-bearing animals. Other investigators have used cyclophosphamide 
or irradiation to reduce suppressor T cell populations in the reci-
pient animals (Fernandez-Cruz et al., 1980; Greenberg et al., 1981; 
Lee et al., 1984). Greenberg et al. (1981) found that immune cell 
therapy without accompanying chemotherapy treatment had no apparent 
antitumor effect in vivo. Cyclophosphamide had a direct antitumor 
effect (Greenberg et al., 1980) as well as potentially facilitating 
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host immune responses. In the current investigation, effects against 
EL-4 were observed even without treatment of host T cell populations. 
IL-1 therapy in this tumor system allows for the generation of lymph 
node cells which are therapeutically effective in naive animals. The 
therapeutic efficacy of these cells requires neither in vitro manipu-
lation of the cells, nor additional treatment of the host immune sys-
tem. 
Lymph node cells derived from IL-1 treated animals 7 days post 
tumor challenge did not exhibit direct cytotoxicity to the tumor in in 
vitro assays. However, these cells were effective in host protection 
against the EL-4 in the adoptive transfer assays. This apparent dis-
crepancy between in vivo and in vitro activities has been observed by 
other investigators in a number of adoptive transfer systems (Green-
berg et al., 1981; Fujiwara et al., 1984; Lee et al., 1984; Shu and 
Rosenberg, 1985). These observations imply that tumor resistance can 
be transferred with cells which are non-cytotoxic in vitro, and that 
the lymphocytes circulate in a state lacking direct cytotoxic ability. 
The adoptively transferred cells may function to recruit host effec-
tors, or may require stimulation by the tumor to become active them-
selves. 
In several adoptive immunotherapy models, CD4+coa- cells have 
been shown to play a major role in the transfer of immunity (Greenberg 
et al., 1981; Fujiwara et al., 1984; Lee et al., 1984). Greenberg et 
al. (1981) demonstrated that depletion of non-cytotoxic (non-cos+) 
cell populations did not affect animal survival, while the depletion 
of co4+ or Thy 1+ cells abrogated the therapeutic effect. These lym-
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phocytes may interact locally with tumor cells at the tumor site and 
may generate cytotoxic effectors. The implication in many of these 
systems is that helper T lymphocytes, adoptively transferred into 
tumor-bearing animals, recruit and activate cytotoxic T lymphocyte 
(CTL) precursors in the host animal. In immunogenic tumor models, the 
CD4+ lymphocytes may activate host CTL precursors in vivo (Greenberg 
et al., 1981). While the adoptively transferred cells stimulate 
tumor-specific immunity in these systems, it appears that the 
cytotoxicity generated may have some non-specific components (Crum, 
1987). In the weakly immunogenic EL-4 system, the presence of some 
donor effectors may also be required, as suggested by the depletion 
experiments. The lymphocytes are potentially cytotoxic, but require 
stimulation to become activated. For example, the therapeutically 
effective day 7 lymph node cells, when stimulated with IL-2, showed 
cytotoxic activity against several tumor targets (Fig. 11). 
Lymph node cells from day 3 and 5 post tumor challenge have no 
effect in the adoptive transfer assays; however, in subsequent in 
vitro experiments, these cells showed the potential for cytotoxic ac-
tivity (Fig. 11). In contrast, the lymph node cells from day 7 
animals did promote delayed tumor development and enhanced animal 
survival in the adoptive transfer assays. These observations suggest 
that day 3 and 5 cells have the potential to affect tumor immune re-
sponses. By 7 days after tumor challenge further development in the 
lymph nodes has occurred, and the cells are capable therefore of 
mediating tumor protective effects against EL-4. In the limiting 
dilution analysis and bulk culture systems, the addition of exogenous 
89 
IL-2 may allow for the maturation of day 3 and 5 cells, and this ma-
turation is reflected in the in vitro assays (Fig. 11-14). 
While IL-1 therapy has been shown to enhance tumor survival in a 
number of tumor models (Nakamura et al., 1986; North et al., 1988; 
McCune and Marquis, 1990), the ability of IL-1 to affect local immune 
responsiveness has not been examined previously. This investigation 
assessed IL-1 effects on cytotoxic and proliferative responses in the 
lymph nodes draining the site of tumor challenge. Investigations were 
performed to determine the effect of IL-1 therapy on the cytotoxic 
ability of local lymphocyte populations. These experiments demon-
strated that lymph node cells from IL-1 treated animals have enhanced 
cytotoxic potential when compared to lymph node cells of animals that 
did not receive IL-1. Lymph node cells obtained directly from tumor-
bearing animals did not exhibit significant cytotoxicity against EL-4, 
YAC-1, or P815 tumor targets. However, after stimulation with IL-2 in 
vitro, activity was generated against all three tumors (Fig. 11). The 
lack of cytotoxic activity in freshly isolated lymph node cells has 
also been observed in antigenic systems, and may be due to premature 
arrest of the differentiation pathway (Vanhaesebroeck et al., 1989). 
Importantly, lymph node cells from IL-1 treated animals 
demonstrated enhanced cytotoxic potential when compared to cells from 
non-IL-1 treated animals. The enhanced cytotoxic potential was shown 
by increased cytotoxic cell frequency and significantly higher total 
lytic activity following IL-2 stimulation (Fig. 11-14). The differen-
ces in total lytic activity were predominantly due to the increased 
lymph node cell number observed in the IL-1 treated animals. The 
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addition of exogenous IL-2 in vitro was necessary to reveal the dif-
ferences between the IL-1 treated and non-IL-1 treated groups. The in 
vivo effects of IL-1 treatment may be difficult to measure in vitro, 
and IL-2 may function to amplify these effects. The increased fre-
quency of cytotoxic cells occurred within 2 to 4 days of tumor chal-
lenge, and was associated with the enhancement in lymph node cell num-
ber. 
IL-1 treated animals demonstrated enhanced total cytotoxic poten-
tial and increased cytotoxic cell frequency against all tumor targets 
assessed. Because of the method by which these cells were generated, 
a number of factors could lead to enhanced cytotoxicity. Increased 
cytotoxicity following stimulation with IL-2 in vitro may be due to 
increased cytotoxic ability of individual cells, increased ability of 
cells to survive in IL-2, or increased frequency of cytotoxic cells. 
In the bulk culture system, numerous interactions may occur between 
various cell populations, making it difficult to assess the reasons 
for enhanced cytotoxicity. 
Limiting dilution analysis has been used to analyze the fre-
quency of CTL precursors for a variety of antigens (Miller, 1982). In 
the current study, the ability of IL-1 to modulate the frequency of 
cytotoxic cells with multiple target specificities was examined. IL-1 
treated animals demonstrated increased cytotoxic cell frequency when 
compared to animals which received adjuvant therapy alone (Fig. 12, 
13). Statistically significant increases in frequency occurred early 
after tumor challenge in the IL-1 treated group (Table 7). A greater 
number of effector cells may develop in the IL-1 treated animals due 
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to lymphokine stimuli received in vivo. Vanhaesebroeck et al. (1989) 
suggest that an ongoing immune response may activate LAK precursor 
cells to reach a state of maturation that lies closer to the LAK ef-
fector stage. Lymph node cells from animals undergoing an immune 
response (such as the IL-1 treated animals) may therefore be further 
on the way to mature effectors. This may facilitate immune responses 
in vivo because these cells would theoretically require less subse-
quent stimulation to become cytotoxic. 
In addition, the cells from the IL-1 treated animals may be 
better able to respond to IL-2. Increased cytotoxic cell frequency 
correlates with an enhanced lymphocyte responsiveness to IL-2 (Fig. 9, 
12, 13). IL-1 may act directly on the cytotoxic cells by enhancing 
their responsiveness to IL-2, allowing for greater expansion in cell 
number following activation. Alternatively, IL-1 may act on another 
cell population, which in turn affects cytotoxic cell development or 
maturation, perhaps through the production of cytokines such as IL-2 
or IL-4 (Widmer et al., 1987; Trenn et al., 1988). 
Increased cytotoxic cell frequency was observed in the IL-1 
treated animals on the same days in which IL-1 induced enhanced lymph 
node cell numbers (Table S, 7). This correlation of increased cell 
number and increased frequency suggests that the accumulation of cyto-
toxic cells in the IL-1 treated animals may be related to the increase 
in lymph node cell number. The IL-1 induced increase in cytolytic 
cell frequency appeared to be dose dependent (Fig. 14). Animals which 
received a lower dose of IL-1 showed a more modest increase in fre-
quency as compared to animals which received the higher dose. Similar 
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dose dependence is observed in the increase in lymph node cell number, 
and also in the IL-1 mediated tumor immunity in this system (Hornung, 
dissertation, 1987). The cell number increase may also represent an 
expansion of helper and/or memory cells. 
Limiting dilution analysis gives the lower limit to the true 
frequency (Miller, 1982). The cytotoxic cell frequencies generated by 
the limiting dilution analysis experiments are modest in comparison to 
the frequencies of CTL precursors found in more antigenic systems. 
The weakly immunogenic nature of the EL-4 lymphoma (Cantrell et al., 
1979) is the most probable reason for this difference. Another factor 
may be reduced immune responsiveness due to the presence of the tumor. 
It could be suggested that the low frequencies and the differences 
between bulk and limiting dilution analysis cytotoxicity could be due 
to an insufficient amount of IL-2 in culture. The possibility that 
insufficient IL-2 was present is unlikely, however, because the amount 
of IL-2 used in the limiting dilution experiments was at least twice 
that used in the bulk culture system. The amount of IL-2 is in the 
range found to generate maximal cytolytic activity in murine lymph 
node cells (Gao et al., 1987). In addition, linear plots were ob-
tained when the input cell number was graphed against the fraction of 
negative wells. This demonstrates that only one necessary component 
was limiting. Linear graphs were obtained for lymph node cells from 
both IL-1 treated and non-IL-1 treated animals, allowing for an ac-
curate comparison of cytolytic cell frequency between the treatment 
groups. 
When properly performed, limiting dilution analysis measures 
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only one limiting factor, which is the number of precursor cells. A 
straight line graph indicates a single-hit curve which is evidence for 
a single limiting cell type (Lefkovits and Waldmann, 1984). Non-lin-
ear curves indicate inadequate culture conditions and/or complex cel-
lular interactions. The two types of non-linear curves are multi-
target and multihit. A multitarget curve reflects the need for two or 
more different cell types to generate effector activities. These 
curves have a definite linear portion which may be extrapolated to the 
y-axis to determine the number of cells involved. A multihit curve is 
characterized by no definite slope. No extrapolation to the axis is 
possible. Such curves reflect the need for two or more cells of the 
same kind to interact. A third type of non-linear curve is one in 
which "leveling off" occurs. At higher cell inputs, where the precur-
sor cells are saturating, another cell type becomes limiting. The 
curve asymptotically approaches a particular value for y (the fraction 
of negative cultures per total number of cultures). The graphs gener-
ated in this investigation corresponded to the single-hit straight 
line type (Fig. 12, 13). Preliminary experiments with lower amounts 
of IL-2 produced non-linear graphs which resembled multitarget curves. 
In these graphs, linear portions were present between 5 x 104 and 1 x 
105 input cells, with a curved portion approaching a y value of 1.0 at 
1 x 104 cells. 
The limiting dilution analysis results can be used to suggest 
possible mechanisms for cytotoxic effector development. The use of 
suboptimal IL-2 concentrations with low lymph node cell numbers 
generated non-linear precursor plots. Addition of sufficient ex-
94 
ogenous IL-2 allowed for a linear response. Other investigators have 
noted similar culture requirements in the limiting dilution analysis 
of CTL precursors (Horohov et al., 1988; Fischer-Lindahl and Wilson, 
1977; Teh et al., 1977a; Teh et al., 1977b; Skinner and Marbrook, 
1976). One or more of the cells required for the production of IL-2 
can be diluted out by limiting dilution before the culture becomes 
limiting for CTL precursors (Miller, 1982). This effect suggests the 
involvement of an additional cell-type in the development of cytotoxic 
activity; this cell may be diluted out at the low responder cell num-
bers. Individual wells in the limiting dilution assay had much fewer 
cells than those in the bulk culture system (l/25th to l/250th of the 
number). Therefore it is not surprising that a necessary additional 
factor may be limiting at the lower cell numbers. 
Missing cell populations may produce cytokines necessary for the 
expansion and maturation of cytotoxic cells. Because the cytotoxic 
activity generated is against several tumor targets, but the immunity 
to the tumor is specific, it could be postulated that the cell which 
is diluted out may be the immunologically specific component. In this 
model, IL-1 could affect the generation of a specific T helper-type 
cell, which in turn produces cytokines to stimulate the production of 
non-specific cytotoxic effectors. These cell populations may also 
develop in the non-IL-1 treated animals, but at a number insufficient 
to allow for immunity upon secondary tumor challenge. Generally, 
there is a greater difference between the cytotoxicity generated in 
the bulk and limiting dilution assays when lymph node cells from non-
IL-1 treated animals are used (e.g. no cytotoxicity against P815 under 
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limiting dilution conditions). A lower number of these helper-type 
cells in the non-IL-1 treated animals could contribute to this dis-
crepancy. 
The limiting dilution analysis data suggest possible mechanisms 
for IL-1 action in this experimental model. Little specific CTL 
response to EL-4 has been found in this system. This observation is 
consistent with the weakly immunogenic nature of the tumor (Gorer, 
1950; Cantrell et al., 1979). The limiting dilution analysis per-
formed in this study further reinforces this observation. Reactivity 
against EL-4 develops concomitantly with reactivity against PS15, and 
slightly after YAC-1 reactivity. These data suggest the possibility 
of more than one effector population, one with NK-like activity and 
one with a broader range of reactivity. Local induction of non-speci-
fic effectors has been implicated in the development of in vivo tumor 
resistance (Crum, 19S7). Lymph node cells from IL-1 treated animals 
should be better able to respond to in vivo stimulus to become cyto-
toxic effectors. 
The general enhancement of potential cytotoxic function seen 
with lymph node cells from IL-1 treated animals may be related to the 
increase in cos+ cells observed in the regional lymph nodes. Sig-
nificantly enhanced numbers of cos+ cells were present in the IL-1 
treated animals on days 2, 3 and 4 post tumor challenge. This cell 
number increase could represent an expansion of cytotoxic precursor 
and/or effector cells which have a role in the immune response to the 
tumor. 
The ability of lymph node cells from IL-1 treated animals to 
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adoptively transfer immunity to the tumor suggests the development of 
memory populations reactive to the tumor. The results of the anti-
genic stimulation experiments provide evidence for the presence of 
cells reactive to EL-4 in the lymph nodes following secondary chal-
lenge with the tumor. Experiments showed that lymph node cells from 
IL-1 treated animals demonstrate enhanced proliferation in response to 
EL-4 stimulation in vitro following secondary challenge in vivo. This 
responsiveness was predominantly tumor-specific as indicated by the 
low level of proliferation in response to LLC stimulation in vitro 
(Fig. 15). The presence of EL-4-reactive cells in the lymph nodes of 
IL-1 treated animals may be important in the immune response to the 
tumor. 
Previously, it has been shown that a low level of reactivity to 
EL-4 is present in the spleens of animals undergoing secondary chal-
lenge (Hornung, dissertation, 1987). In those experiments, the stimu-
lation indices obtained ranged from 3.0 to 3.75 for the IL-1 treated 
and 1.5 to 2.0 for the non-IL-1 treated. The ability of cells to 
proliferate in response to EL-4 suggests that the tumor expresses some 
antigenic determinants to which an immune response can be produced. 
In the current investigation, lymph node cells from the IL-1 treated 
animals show enhanced reactivity as compared to cells from non-IL-1 
treated animals. Some reactivity was present on day 10 post tumor 
challenge, but day 14 cells showed the greatest responsiveness of the 
days measured. The stimulation indices for the IL-1 treated animals 
were 11.9 ± 1.6 for the EL-4 and 2.2 ± 0.6 for LLC. The responsive-
ness in the lymph nodes was substantially higher than that seen pre-
97 
viously in the spleen. In contrast, lymph node cells from non-IL-1 
treated animals did not exhibit enhanced responsiveness to EL-4 by day 
14 post challenge. Lymph node cells derived more than 14 days post 
tumor challenge were not examined to determine if a shift in the kin-
etics of the response could be responsible for this difference. Lymph 
node cells derived at time points later than 14 days may contain EL-4 
cells, and therefore accurate assessments can not be performed using 
these cells. However, even if reactivity were to develop after day 14 
in the non-IL-1 treated animals, it would be too late to prevent tumor 
development and subsequent animal mortality. 
Although lymph node cells from the IL-1 treated animals showed 
enhanced proliferation in response to EL-4, a low level of prolifera-
tion occurred in response to LLC stimulation in vitro (Fig. 15, panel 
A.). This indicates a non-specific component in the response gener-
ated by IL-1 and EL-4 in vivo. The stimulation of tumor-specific 
cells would lead to the elaboration of cytokines, and an overall in-
crease in responsiveness. Animals which did not receive IL-1 at the 
time of primary tumor challenge did not show proliferation in response 
to LLC. Lymph node cells from animals undergoing primary tumor chal-
lenge did not proliferate in response to EL-4 in vitro. When examin-
ing animals undergoing primary tumor challenge, there is no way to 
determine which animals will survive and subsequently develop tumor 
immunity. Therefore, the lack of responsiveness to EL-4 in the pri-
mary challenge animals may be due to the presence of cells from non-
protected animals. By looking at animals which have already survived 
the tumor challenge, the percentage of immune cells was increased. 
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Animals were rechallenged in vivo with either EL-4 or LLC. Memory 
cells may develop at the time of primary tumor challenge, but require 
secondary stimulation in vivo for a sufficient expansion in number to 
occur to allow for measurement in vitro. A secondary challenge in 
vivo also allows for increased numbers of antigen-reactive cells in 
the draining lymph nodes by attracting circulating lymphocytes to the 
region (Cohen and Livnat, 1976). 
Experiments were performed to determine the effect of IL-1 ther-
apy on the proliferative responses of lymph node cells from primary 
and secondary challenge animals. These investigations revealed that 
IL-1 treatment enhanced the ability of lymph node cells from animals 
undergoing primary tumor challenge to respond to IL-2 as judged by 
enhanced proliferation and increased recoverable cell numbers (Fig. 9, 
10). IL-1 augmentation of lymph node cell responsiveness was as-
sociated temporally with the increases in lymph node cell number and 
cytotoxic potential. Lymph node cells from IL-1 treated animals un-
dergoing primary tumor challenge showed an enhanced proliferative 
response to IL-2, which resulted in an increased cell number following 
stimulation with IL-2 (Fig. 9, 10). This effect was noted on days 3 
and 5 post tumor challenge, but not on day 4. IL-1 therapy was ad-
ministered on alternating days begin-ning on the day of tumor chal-
lenge (day 0). Animals which received IL-1 18 to 24 hours before 
their lymph nodes were removed, showed enhanced lymphoproliferation. 
In contrast, animals which received IL-1 42 to 48 hours before lymph 
node removal did not. It appears that IL-2 responsiveness was en-
hanced in correspondence to the administration of IL-1 therapy. The 
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delay between IL-1 administration and the increase in IL-2 responsive-
ness implies that the IL-1 effect is indirect. However, the increased 
IL-2 inducible cell number in the IL-1 treated animals represents an 
increased potential for tumor reactivity in the draining lymph nodes. 
In addition, the increase demonstrates that the enhanced proliferative 
ability of the lymph node cells from the IL-1 treated animals leads to 
increased viability and cell number in vitro. The enhanced ability to 
respond to IL-2 may result in the expansion of host protective cell 
subsets in the IL-1 treated animals. 
Increases in cell populations could be important in the genera-
tion of cytotoxic responses, as well as in subsequent immunity to the 
tumor. The increased responsiveness to IL-2 in vitro exhibited by the 
lymph node cells from the IL-1 treated animals has implications for 
enhanced immune responsiveness in vivo. An enhanced proliferative 
ability may lead to the expansion of cell populations important in 
cytotoxic and helper responses. A more responsive cytotoxic popula-
tion would result in greater cytotoxic ability due to a quicker re-
sponse. Quicker responsiveness could be important in the early re-
sponse to tumors allowing for survival and immunity. Increased re-
sponsiveness in helper populations could result in increased cytokine 
production and may allow for enhanced development of memory popula-
tions. 
Based on the observations of this study, IL-1 may be valuable as 
an immunoaugmenting agent in conjunction with other forms of tumor 
therapy. This study demonstrates that systemic IL-1 treatment affects 
immune parameters in the regional lymph nodes of animals undergoing 
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adjuvant therapy. The regional lymph nodes of IL-1 treated animals 
demonstrated increased lymph node cell number, enhanced numbers of T 
lymphocytes, and increased cytotoxic cell frequency. Some of these 
cells were capable of mediating effects against EL-4 in naive animals. 
This is the first investigation which has identified immune enhancing 
effects of IL-1 in a weakly immunogenic tumor model in which IL-1 
treatment provides for tumor immunity. These effects may be related 
to the immune response to the tumor and subsequent development of 
protective immunity. Because some of these effects were enhanced by 
exogenous IL-2, the in vivo administration of IL-2 in conjunction with 
IL-1 may increase the therapeutic effects. 
The results of this study suggest that the immune-enhancing 
activities of IL-1 would make it a useful adjunct to other therapeutic 
modalities in the treatment of neoplasia. These results are consis-
tent with the hypothesis that IL-1 mediates an immunological response 
which is tumor-protective in this experimental model. This study 
suggests several areas of investigation to further elucidate the role 
of IL-1 in the generation of tumor immunity. Among these are an ex-
amination of cellular interactions at the tumor site, and an evalua-
tion of the role of CD4+ lymphocytes in the generation and maintenance 
of tumor immunity. Information about which lymphocyte populations 
reach the tumor site and what interactions occur could be used to 
evaluate the relevance of the immune enhancing effects of IL-1 to the 
tumor immune response. CD4+ lymphocytes have been suggested as medi-
ators of tumor immune effects in various experimental tumor models 
(Greenberg et al., 1981; Fujiwara et al., 1984). A more careful eval-
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uation of these cells in the primary and secondary responses to the 
tumor may reveal their role in the IL-1 induced immunity in this tumor 
model. 
SUMMARY 
The objective of this study was to investigate the local lym-
phoid responsiveness generated by IL-1 treatment in an experimental 
murine tumor model, and to evaluate the relationship between this 
lymphoid responsiveness and the induction of apparent tumor immunity. 
This model was selected because IL-1 treatment, in conjunction with 
local adjuvant therapy, allows for the generation of apparent tumor-
specific immunity to the weakly immunogenic EL-4 lymphoma. 
This study demonstrated that systemic administration of IL-1 
modifies local immune responses in animals undergoing adjuvant therapy 
for a primary tumor. IL-1 treatment enhanced immune responsiveness in 
the lymph nodes draining the site of tumor challenge as demonstrated 
by increased lymph node cell number, enhanced numbers of T lym-
phocytes, and increased cytotoxic potential. Animals which received 
IL-1 and adjuvant therapy showed a significantly higher increase in 
draining lymph node cell number following tumor challenge. The cell 
number increase correlated with an over~ll increase in C04+, cos+, and 
Thy 1.2+ cells. Approximately SO to SS% of the cell number increase 
could be accounted for by the increase in Thy 1.2+ lymphocytes. The 
increase in Thy 1.2+ cells represented an overall increase in cell 
number, and not a specific or selective increase in either co4+ or 
cos+ lymphocytes. 
Experiments which evaluated the cytotoxic ability of local lym-
phocyte populations showed that lymph node cells from IL-1 treated 
animals have enhanced cytotoxic potential when compared to lymph node 
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cells of animals that did not receive IL-1, as demonstrated by in-
creased cytotoxic cell frequency. IL-1 treatment enhanced the ability 
of lymph node cells from animals undergoing primary tumor challenge to 
respond to IL-2 as judged by enhanced proliferation and increased 
recoverable cell numbers. IL-1 augmentation of lymph node cell 
responsiveness was associated temporally with increases in lymph node 
cell number and cytotoxic potential. Lymph node cells from IL-1 
treated animals demonstrated enhanced proliferation in response to EL-
4 stimulation in vitro following secondary challenge in vivo. This 
responsiveness was predominantly tumor-specific as indicated by the 
low level of proliferation in response to an antigenically distinct 
tumor in vitro. The presence of relevant tumor-reactive cells in the 
lymph nodes of IL-1 treated animals may be important in the immune re-
sponse to the tumor. 
Utilizing adoptive transfer of tumor resistance as an assay of 
in vivo activity, this study also demonstrated that systemic IL-1 
treatment affects the tumor-protective capacity of the regional lym-
phoid tissue. Lymph node cells from IL-1 treated animals have an-
titumor effects against EL-4 in vivo, as demonstrated by delayed tumor 
development and enhanced animal survival. Spleen cells derived from 
these same animals had no effect on tumor development or animal sur-
vival, suggesting that responsiveness to the tumor during that time 
period was local and not systemic. 
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